mmitch25/LLM_Course_Project
Text Classification
•
Updated
Dataset Preview
Full Screen Viewer
Full Screen
The full dataset viewer is not available (click to read why). Only showing a preview of the rows.
The dataset generation failed because of a cast error
Error code: DatasetGenerationCastError
Exception: DatasetGenerationCastError
Message: An error occurred while generating the dataset
All the data files must have the same columns, but at some point there are 4 missing columns ({'qid', 'result_rank', 'concept', 'score'})
This happened while the csv dataset builder was generating data using
hf://datasets/mmitch25/sample_awards/sample_awards.csv (at revision 133fdb843990c157d0923f2ca06ebc3586f63401)
Please either edit the data files to have matching columns, or separate them into different configurations (see docs at https://hf.co/docs/hub/datasets-manual-configuration#multiple-configurations)
Traceback: Traceback (most recent call last):
File "/src/services/worker/.venv/lib/python3.9/site-packages/datasets/builder.py", line 2011, in _prepare_split_single
writer.write_table(table)
File "/src/services/worker/.venv/lib/python3.9/site-packages/datasets/arrow_writer.py", line 585, in write_table
pa_table = table_cast(pa_table, self._schema)
File "/src/services/worker/.venv/lib/python3.9/site-packages/datasets/table.py", line 2302, in table_cast
return cast_table_to_schema(table, schema)
File "/src/services/worker/.venv/lib/python3.9/site-packages/datasets/table.py", line 2256, in cast_table_to_schema
raise CastError(
datasets.table.CastError: Couldn't cast
text_hash: string
text: string
-- schema metadata --
pandas: '{"index_columns": [{"kind": "range", "name": null, "start": 0, "' + 487
to
{'text_hash': Value(dtype='string', id=None), 'text': Value(dtype='string', id=None), 'qid': Value(dtype='string', id=None), 'score': Value(dtype='float64', id=None), 'concept': Value(dtype='string', id=None), 'result_rank': Value(dtype='int64', id=None)}
because column names don't match
During handling of the above exception, another exception occurred:
Traceback (most recent call last):
File "/src/services/worker/src/worker/job_runners/config/parquet_and_info.py", line 1321, in compute_config_parquet_and_info_response
parquet_operations = convert_to_parquet(builder)
File "/src/services/worker/src/worker/job_runners/config/parquet_and_info.py", line 935, in convert_to_parquet
builder.download_and_prepare(
File "/src/services/worker/.venv/lib/python3.9/site-packages/datasets/builder.py", line 1027, in download_and_prepare
self._download_and_prepare(
File "/src/services/worker/.venv/lib/python3.9/site-packages/datasets/builder.py", line 1122, in _download_and_prepare
self._prepare_split(split_generator, **prepare_split_kwargs)
File "/src/services/worker/.venv/lib/python3.9/site-packages/datasets/builder.py", line 1882, in _prepare_split
for job_id, done, content in self._prepare_split_single(
File "/src/services/worker/.venv/lib/python3.9/site-packages/datasets/builder.py", line 2013, in _prepare_split_single
raise DatasetGenerationCastError.from_cast_error(
datasets.exceptions.DatasetGenerationCastError: An error occurred while generating the dataset
All the data files must have the same columns, but at some point there are 4 missing columns ({'qid', 'result_rank', 'concept', 'score'})
This happened while the csv dataset builder was generating data using
hf://datasets/mmitch25/sample_awards/sample_awards.csv (at revision 133fdb843990c157d0923f2ca06ebc3586f63401)
Please either edit the data files to have matching columns, or separate them into different configurations (see docs at https://hf.co/docs/hub/datasets-manual-configuration#multiple-configurations)Need help to make the dataset viewer work? Make sure to review how to configure the dataset viewer, and open a discussion for direct support.
text_hash
string | text
string | qid
string | score
float64 | concept
string | result_rank
int64 |
|---|---|---|---|---|---|
000c24e7d3b5ae3c56c9c87ad2cca4330c1f05ca | Abstract
The objective of this NIH Phase II SBIR proposal is to demonstrate the commercial feasibility of IsoTag™, a
novel cost-effective method to purify monoclonal antibodies (mAbs) that eliminates the need for Protein A (PrA)
chromatography. This objective will be achieved by using a recombinant fusion comprised of a stimulus
responsive elastin-like polypeptide (ELP) that can undergo a reversible soluble to insoluble phase transition,
and the Z-domain (ZD) derived from PrA that binds the constant region of mAbs with high affinity and
specificity. This proposal is motivated by the fact that the first and critical step of mAb purification —PrA
affinity chromatography— has not kept pace with improvements in the recombinant expression level of mAbs,
creating a bottleneck in their production. IsoTag™, which combines affinity capture of mAbs and their isolation
by triggered phase separation with microfiltration, addresses this bottleneck. Upon addition of the ELP-ZD
fusion to clarified cell culture harvest, the ELP-ZD binds the mAb. Upon triggering the phase transition of the
mAb/ELP-ZD with a small amount of kosmotropic salt, the mAb/ELP-ZD complex undergoes liquid-liquid phase
separation into micron-sized droplets, allowing it to be separated from all soluble contaminants by continuous
tangential flow filtration, Next, the pH is lowered to ~4.0, which causes the ZD to lose its affinity for the mAb.
The pure, eluted mAb is in the soluble phase and the ELP-ZD can be regenerated from the insoluble phase. In
the NIH funded Phase I of this project, we have fully optimized the ELP-ZD and the process parameters for
IsoTag™ purification. We have shown that at the bench scale, IsoTag™ can be used to successfully isolate
mAb from mammalian cell culture with yields and contaminant removal that outperform commercially available
alternatives (GE Predictor Plate and Thermo Fisher Nab Spin Column). Having established technical feasibility
and developed a research use only, bench scale product, we plan to validate IsoTag™andapos;s commercial feasibility
for large-scale mAb purification in this Phase II proposal. Our Specific Aims to achieve this objective are: (1)
We will optimize microbial production of the ELP-ZD fusion using fermentation and develop a scalable
purification process. We will then perform a 30 L pilot production run and begin developing an ISO9001 quality
control management protocol. (2) We will validate an assay for quantifying residual ELP-ZD. (3) We will
perform side-by-side purification of the NISTmAb at 30 L scale to compare IsoTag™ to leading PrA resins,
MAbSelect SuRe and Amsphere A3. Last, we will use BioSolve and Matlab software to develop a model for an
interface that takes a customerandapos;s inputs and calculates a personalized cost savings by switching to IsoTag™.
The outcome of this project will be compelling data that encourages customer conversion. Isolereandapos;s vision is
that IsoTag™ will be a plug-and-play downstream process that allows the industry to achieve fully integrated,
continuous manufacturing where improved productivity and lower cost can make mAbs globally accessible.PROJECT NARRATIVE
Monoclonal antibodies (mAb) are an important and fast growing drug class, but the first phase in
their purification process is a capture step via Protein A chromatography, which requires
expensive resin and equipment making it difficult and time consuming to execute at commercial
scale. Our IsoTag™ technology will provide an innovative, non-chromatographic alternative that
combines affinity/phase separation with microfiltration. IsoTag™ will create a paradigm shift in
the bioprocessing industry with its lower cost and continuous process that offers faster mass
transfer, milder elution conditions, and enhanced productivity. | Q382799 | 0.09312 | Affinity chromatography | 1 |
000c24e7d3b5ae3c56c9c87ad2cca4330c1f05ca | Abstract
The objective of this NIH Phase II SBIR proposal is to demonstrate the commercial feasibility of IsoTag™, a
novel cost-effective method to purify monoclonal antibodies (mAbs) that eliminates the need for Protein A (PrA)
chromatography. This objective will be achieved by using a recombinant fusion comprised of a stimulus
responsive elastin-like polypeptide (ELP) that can undergo a reversible soluble to insoluble phase transition,
and the Z-domain (ZD) derived from PrA that binds the constant region of mAbs with high affinity and
specificity. This proposal is motivated by the fact that the first and critical step of mAb purification —PrA
affinity chromatography— has not kept pace with improvements in the recombinant expression level of mAbs,
creating a bottleneck in their production. IsoTag™, which combines affinity capture of mAbs and their isolation
by triggered phase separation with microfiltration, addresses this bottleneck. Upon addition of the ELP-ZD
fusion to clarified cell culture harvest, the ELP-ZD binds the mAb. Upon triggering the phase transition of the
mAb/ELP-ZD with a small amount of kosmotropic salt, the mAb/ELP-ZD complex undergoes liquid-liquid phase
separation into micron-sized droplets, allowing it to be separated from all soluble contaminants by continuous
tangential flow filtration, Next, the pH is lowered to ~4.0, which causes the ZD to lose its affinity for the mAb.
The pure, eluted mAb is in the soluble phase and the ELP-ZD can be regenerated from the insoluble phase. In
the NIH funded Phase I of this project, we have fully optimized the ELP-ZD and the process parameters for
IsoTag™ purification. We have shown that at the bench scale, IsoTag™ can be used to successfully isolate
mAb from mammalian cell culture with yields and contaminant removal that outperform commercially available
alternatives (GE Predictor Plate and Thermo Fisher Nab Spin Column). Having established technical feasibility
and developed a research use only, bench scale product, we plan to validate IsoTag™andapos;s commercial feasibility
for large-scale mAb purification in this Phase II proposal. Our Specific Aims to achieve this objective are: (1)
We will optimize microbial production of the ELP-ZD fusion using fermentation and develop a scalable
purification process. We will then perform a 30 L pilot production run and begin developing an ISO9001 quality
control management protocol. (2) We will validate an assay for quantifying residual ELP-ZD. (3) We will
perform side-by-side purification of the NISTmAb at 30 L scale to compare IsoTag™ to leading PrA resins,
MAbSelect SuRe and Amsphere A3. Last, we will use BioSolve and Matlab software to develop a model for an
interface that takes a customerandapos;s inputs and calculates a personalized cost savings by switching to IsoTag™.
The outcome of this project will be compelling data that encourages customer conversion. Isolereandapos;s vision is
that IsoTag™ will be a plug-and-play downstream process that allows the industry to achieve fully integrated,
continuous manufacturing where improved productivity and lower cost can make mAbs globally accessible.PROJECT NARRATIVE
Monoclonal antibodies (mAb) are an important and fast growing drug class, but the first phase in
their purification process is a capture step via Protein A chromatography, which requires
expensive resin and equipment making it difficult and time consuming to execute at commercial
scale. Our IsoTag™ technology will provide an innovative, non-chromatographic alternative that
combines affinity/phase separation with microfiltration. IsoTag™ will create a paradigm shift in
the bioprocessing industry with its lower cost and continuous process that offers faster mass
transfer, milder elution conditions, and enhanced productivity. | Q425941 | 0.051266 | Protein A | 2 |
000c24e7d3b5ae3c56c9c87ad2cca4330c1f05ca | Abstract
The objective of this NIH Phase II SBIR proposal is to demonstrate the commercial feasibility of IsoTag™, a
novel cost-effective method to purify monoclonal antibodies (mAbs) that eliminates the need for Protein A (PrA)
chromatography. This objective will be achieved by using a recombinant fusion comprised of a stimulus
responsive elastin-like polypeptide (ELP) that can undergo a reversible soluble to insoluble phase transition,
and the Z-domain (ZD) derived from PrA that binds the constant region of mAbs with high affinity and
specificity. This proposal is motivated by the fact that the first and critical step of mAb purification —PrA
affinity chromatography— has not kept pace with improvements in the recombinant expression level of mAbs,
creating a bottleneck in their production. IsoTag™, which combines affinity capture of mAbs and their isolation
by triggered phase separation with microfiltration, addresses this bottleneck. Upon addition of the ELP-ZD
fusion to clarified cell culture harvest, the ELP-ZD binds the mAb. Upon triggering the phase transition of the
mAb/ELP-ZD with a small amount of kosmotropic salt, the mAb/ELP-ZD complex undergoes liquid-liquid phase
separation into micron-sized droplets, allowing it to be separated from all soluble contaminants by continuous
tangential flow filtration, Next, the pH is lowered to ~4.0, which causes the ZD to lose its affinity for the mAb.
The pure, eluted mAb is in the soluble phase and the ELP-ZD can be regenerated from the insoluble phase. In
the NIH funded Phase I of this project, we have fully optimized the ELP-ZD and the process parameters for
IsoTag™ purification. We have shown that at the bench scale, IsoTag™ can be used to successfully isolate
mAb from mammalian cell culture with yields and contaminant removal that outperform commercially available
alternatives (GE Predictor Plate and Thermo Fisher Nab Spin Column). Having established technical feasibility
and developed a research use only, bench scale product, we plan to validate IsoTag™andapos;s commercial feasibility
for large-scale mAb purification in this Phase II proposal. Our Specific Aims to achieve this objective are: (1)
We will optimize microbial production of the ELP-ZD fusion using fermentation and develop a scalable
purification process. We will then perform a 30 L pilot production run and begin developing an ISO9001 quality
control management protocol. (2) We will validate an assay for quantifying residual ELP-ZD. (3) We will
perform side-by-side purification of the NISTmAb at 30 L scale to compare IsoTag™ to leading PrA resins,
MAbSelect SuRe and Amsphere A3. Last, we will use BioSolve and Matlab software to develop a model for an
interface that takes a customerandapos;s inputs and calculates a personalized cost savings by switching to IsoTag™.
The outcome of this project will be compelling data that encourages customer conversion. Isolereandapos;s vision is
that IsoTag™ will be a plug-and-play downstream process that allows the industry to achieve fully integrated,
continuous manufacturing where improved productivity and lower cost can make mAbs globally accessible.PROJECT NARRATIVE
Monoclonal antibodies (mAb) are an important and fast growing drug class, but the first phase in
their purification process is a capture step via Protein A chromatography, which requires
expensive resin and equipment making it difficult and time consuming to execute at commercial
scale. Our IsoTag™ technology will provide an innovative, non-chromatographic alternative that
combines affinity/phase separation with microfiltration. IsoTag™ will create a paradigm shift in
the bioprocessing industry with its lower cost and continuous process that offers faster mass
transfer, milder elution conditions, and enhanced productivity. | Q7211373 | 0.04762 | Monoclonal antibodies | 3 |
000c24e7d3b5ae3c56c9c87ad2cca4330c1f05ca | Abstract
The objective of this NIH Phase II SBIR proposal is to demonstrate the commercial feasibility of IsoTag™, a
novel cost-effective method to purify monoclonal antibodies (mAbs) that eliminates the need for Protein A (PrA)
chromatography. This objective will be achieved by using a recombinant fusion comprised of a stimulus
responsive elastin-like polypeptide (ELP) that can undergo a reversible soluble to insoluble phase transition,
and the Z-domain (ZD) derived from PrA that binds the constant region of mAbs with high affinity and
specificity. This proposal is motivated by the fact that the first and critical step of mAb purification —PrA
affinity chromatography— has not kept pace with improvements in the recombinant expression level of mAbs,
creating a bottleneck in their production. IsoTag™, which combines affinity capture of mAbs and their isolation
by triggered phase separation with microfiltration, addresses this bottleneck. Upon addition of the ELP-ZD
fusion to clarified cell culture harvest, the ELP-ZD binds the mAb. Upon triggering the phase transition of the
mAb/ELP-ZD with a small amount of kosmotropic salt, the mAb/ELP-ZD complex undergoes liquid-liquid phase
separation into micron-sized droplets, allowing it to be separated from all soluble contaminants by continuous
tangential flow filtration, Next, the pH is lowered to ~4.0, which causes the ZD to lose its affinity for the mAb.
The pure, eluted mAb is in the soluble phase and the ELP-ZD can be regenerated from the insoluble phase. In
the NIH funded Phase I of this project, we have fully optimized the ELP-ZD and the process parameters for
IsoTag™ purification. We have shown that at the bench scale, IsoTag™ can be used to successfully isolate
mAb from mammalian cell culture with yields and contaminant removal that outperform commercially available
alternatives (GE Predictor Plate and Thermo Fisher Nab Spin Column). Having established technical feasibility
and developed a research use only, bench scale product, we plan to validate IsoTag™andapos;s commercial feasibility
for large-scale mAb purification in this Phase II proposal. Our Specific Aims to achieve this objective are: (1)
We will optimize microbial production of the ELP-ZD fusion using fermentation and develop a scalable
purification process. We will then perform a 30 L pilot production run and begin developing an ISO9001 quality
control management protocol. (2) We will validate an assay for quantifying residual ELP-ZD. (3) We will
perform side-by-side purification of the NISTmAb at 30 L scale to compare IsoTag™ to leading PrA resins,
MAbSelect SuRe and Amsphere A3. Last, we will use BioSolve and Matlab software to develop a model for an
interface that takes a customerandapos;s inputs and calculates a personalized cost savings by switching to IsoTag™.
The outcome of this project will be compelling data that encourages customer conversion. Isolereandapos;s vision is
that IsoTag™ will be a plug-and-play downstream process that allows the industry to achieve fully integrated,
continuous manufacturing where improved productivity and lower cost can make mAbs globally accessible.PROJECT NARRATIVE
Monoclonal antibodies (mAb) are an important and fast growing drug class, but the first phase in
their purification process is a capture step via Protein A chromatography, which requires
expensive resin and equipment making it difficult and time consuming to execute at commercial
scale. Our IsoTag™ technology will provide an innovative, non-chromatographic alternative that
combines affinity/phase separation with microfiltration. IsoTag™ will create a paradigm shift in
the bioprocessing industry with its lower cost and continuous process that offers faster mass
transfer, milder elution conditions, and enhanced productivity. | Q857815 | 0.03506 | Plug and play | 4 |
000c24e7d3b5ae3c56c9c87ad2cca4330c1f05ca | Abstract
The objective of this NIH Phase II SBIR proposal is to demonstrate the commercial feasibility of IsoTag™, a
novel cost-effective method to purify monoclonal antibodies (mAbs) that eliminates the need for Protein A (PrA)
chromatography. This objective will be achieved by using a recombinant fusion comprised of a stimulus
responsive elastin-like polypeptide (ELP) that can undergo a reversible soluble to insoluble phase transition,
and the Z-domain (ZD) derived from PrA that binds the constant region of mAbs with high affinity and
specificity. This proposal is motivated by the fact that the first and critical step of mAb purification —PrA
affinity chromatography— has not kept pace with improvements in the recombinant expression level of mAbs,
creating a bottleneck in their production. IsoTag™, which combines affinity capture of mAbs and their isolation
by triggered phase separation with microfiltration, addresses this bottleneck. Upon addition of the ELP-ZD
fusion to clarified cell culture harvest, the ELP-ZD binds the mAb. Upon triggering the phase transition of the
mAb/ELP-ZD with a small amount of kosmotropic salt, the mAb/ELP-ZD complex undergoes liquid-liquid phase
separation into micron-sized droplets, allowing it to be separated from all soluble contaminants by continuous
tangential flow filtration, Next, the pH is lowered to ~4.0, which causes the ZD to lose its affinity for the mAb.
The pure, eluted mAb is in the soluble phase and the ELP-ZD can be regenerated from the insoluble phase. In
the NIH funded Phase I of this project, we have fully optimized the ELP-ZD and the process parameters for
IsoTag™ purification. We have shown that at the bench scale, IsoTag™ can be used to successfully isolate
mAb from mammalian cell culture with yields and contaminant removal that outperform commercially available
alternatives (GE Predictor Plate and Thermo Fisher Nab Spin Column). Having established technical feasibility
and developed a research use only, bench scale product, we plan to validate IsoTag™andapos;s commercial feasibility
for large-scale mAb purification in this Phase II proposal. Our Specific Aims to achieve this objective are: (1)
We will optimize microbial production of the ELP-ZD fusion using fermentation and develop a scalable
purification process. We will then perform a 30 L pilot production run and begin developing an ISO9001 quality
control management protocol. (2) We will validate an assay for quantifying residual ELP-ZD. (3) We will
perform side-by-side purification of the NISTmAb at 30 L scale to compare IsoTag™ to leading PrA resins,
MAbSelect SuRe and Amsphere A3. Last, we will use BioSolve and Matlab software to develop a model for an
interface that takes a customerandapos;s inputs and calculates a personalized cost savings by switching to IsoTag™.
The outcome of this project will be compelling data that encourages customer conversion. Isolereandapos;s vision is
that IsoTag™ will be a plug-and-play downstream process that allows the industry to achieve fully integrated,
continuous manufacturing where improved productivity and lower cost can make mAbs globally accessible.PROJECT NARRATIVE
Monoclonal antibodies (mAb) are an important and fast growing drug class, but the first phase in
their purification process is a capture step via Protein A chromatography, which requires
expensive resin and equipment making it difficult and time consuming to execute at commercial
scale. Our IsoTag™ technology will provide an innovative, non-chromatographic alternative that
combines affinity/phase separation with microfiltration. IsoTag™ will create a paradigm shift in
the bioprocessing industry with its lower cost and continuous process that offers faster mass
transfer, milder elution conditions, and enhanced productivity. | Q909534 | 0.028964 | Mass transfer | 5 |
000c24e7d3b5ae3c56c9c87ad2cca4330c1f05ca | Abstract
The objective of this NIH Phase II SBIR proposal is to demonstrate the commercial feasibility of IsoTag™, a
novel cost-effective method to purify monoclonal antibodies (mAbs) that eliminates the need for Protein A (PrA)
chromatography. This objective will be achieved by using a recombinant fusion comprised of a stimulus
responsive elastin-like polypeptide (ELP) that can undergo a reversible soluble to insoluble phase transition,
and the Z-domain (ZD) derived from PrA that binds the constant region of mAbs with high affinity and
specificity. This proposal is motivated by the fact that the first and critical step of mAb purification —PrA
affinity chromatography— has not kept pace with improvements in the recombinant expression level of mAbs,
creating a bottleneck in their production. IsoTag™, which combines affinity capture of mAbs and their isolation
by triggered phase separation with microfiltration, addresses this bottleneck. Upon addition of the ELP-ZD
fusion to clarified cell culture harvest, the ELP-ZD binds the mAb. Upon triggering the phase transition of the
mAb/ELP-ZD with a small amount of kosmotropic salt, the mAb/ELP-ZD complex undergoes liquid-liquid phase
separation into micron-sized droplets, allowing it to be separated from all soluble contaminants by continuous
tangential flow filtration, Next, the pH is lowered to ~4.0, which causes the ZD to lose its affinity for the mAb.
The pure, eluted mAb is in the soluble phase and the ELP-ZD can be regenerated from the insoluble phase. In
the NIH funded Phase I of this project, we have fully optimized the ELP-ZD and the process parameters for
IsoTag™ purification. We have shown that at the bench scale, IsoTag™ can be used to successfully isolate
mAb from mammalian cell culture with yields and contaminant removal that outperform commercially available
alternatives (GE Predictor Plate and Thermo Fisher Nab Spin Column). Having established technical feasibility
and developed a research use only, bench scale product, we plan to validate IsoTag™andapos;s commercial feasibility
for large-scale mAb purification in this Phase II proposal. Our Specific Aims to achieve this objective are: (1)
We will optimize microbial production of the ELP-ZD fusion using fermentation and develop a scalable
purification process. We will then perform a 30 L pilot production run and begin developing an ISO9001 quality
control management protocol. (2) We will validate an assay for quantifying residual ELP-ZD. (3) We will
perform side-by-side purification of the NISTmAb at 30 L scale to compare IsoTag™ to leading PrA resins,
MAbSelect SuRe and Amsphere A3. Last, we will use BioSolve and Matlab software to develop a model for an
interface that takes a customerandapos;s inputs and calculates a personalized cost savings by switching to IsoTag™.
The outcome of this project will be compelling data that encourages customer conversion. Isolereandapos;s vision is
that IsoTag™ will be a plug-and-play downstream process that allows the industry to achieve fully integrated,
continuous manufacturing where improved productivity and lower cost can make mAbs globally accessible.PROJECT NARRATIVE
Monoclonal antibodies (mAb) are an important and fast growing drug class, but the first phase in
their purification process is a capture step via Protein A chromatography, which requires
expensive resin and equipment making it difficult and time consuming to execute at commercial
scale. Our IsoTag™ technology will provide an innovative, non-chromatographic alternative that
combines affinity/phase separation with microfiltration. IsoTag™ will create a paradigm shift in
the bioprocessing industry with its lower cost and continuous process that offers faster mass
transfer, milder elution conditions, and enhanced productivity. | Q382783 | 0.028644 | Chemical affinity | 6 |
000c24e7d3b5ae3c56c9c87ad2cca4330c1f05ca | Abstract
The objective of this NIH Phase II SBIR proposal is to demonstrate the commercial feasibility of IsoTag™, a
novel cost-effective method to purify monoclonal antibodies (mAbs) that eliminates the need for Protein A (PrA)
chromatography. This objective will be achieved by using a recombinant fusion comprised of a stimulus
responsive elastin-like polypeptide (ELP) that can undergo a reversible soluble to insoluble phase transition,
and the Z-domain (ZD) derived from PrA that binds the constant region of mAbs with high affinity and
specificity. This proposal is motivated by the fact that the first and critical step of mAb purification —PrA
affinity chromatography— has not kept pace with improvements in the recombinant expression level of mAbs,
creating a bottleneck in their production. IsoTag™, which combines affinity capture of mAbs and their isolation
by triggered phase separation with microfiltration, addresses this bottleneck. Upon addition of the ELP-ZD
fusion to clarified cell culture harvest, the ELP-ZD binds the mAb. Upon triggering the phase transition of the
mAb/ELP-ZD with a small amount of kosmotropic salt, the mAb/ELP-ZD complex undergoes liquid-liquid phase
separation into micron-sized droplets, allowing it to be separated from all soluble contaminants by continuous
tangential flow filtration, Next, the pH is lowered to ~4.0, which causes the ZD to lose its affinity for the mAb.
The pure, eluted mAb is in the soluble phase and the ELP-ZD can be regenerated from the insoluble phase. In
the NIH funded Phase I of this project, we have fully optimized the ELP-ZD and the process parameters for
IsoTag™ purification. We have shown that at the bench scale, IsoTag™ can be used to successfully isolate
mAb from mammalian cell culture with yields and contaminant removal that outperform commercially available
alternatives (GE Predictor Plate and Thermo Fisher Nab Spin Column). Having established technical feasibility
and developed a research use only, bench scale product, we plan to validate IsoTag™andapos;s commercial feasibility
for large-scale mAb purification in this Phase II proposal. Our Specific Aims to achieve this objective are: (1)
We will optimize microbial production of the ELP-ZD fusion using fermentation and develop a scalable
purification process. We will then perform a 30 L pilot production run and begin developing an ISO9001 quality
control management protocol. (2) We will validate an assay for quantifying residual ELP-ZD. (3) We will
perform side-by-side purification of the NISTmAb at 30 L scale to compare IsoTag™ to leading PrA resins,
MAbSelect SuRe and Amsphere A3. Last, we will use BioSolve and Matlab software to develop a model for an
interface that takes a customerandapos;s inputs and calculates a personalized cost savings by switching to IsoTag™.
The outcome of this project will be compelling data that encourages customer conversion. Isolereandapos;s vision is
that IsoTag™ will be a plug-and-play downstream process that allows the industry to achieve fully integrated,
continuous manufacturing where improved productivity and lower cost can make mAbs globally accessible.PROJECT NARRATIVE
Monoclonal antibodies (mAb) are an important and fast growing drug class, but the first phase in
their purification process is a capture step via Protein A chromatography, which requires
expensive resin and equipment making it difficult and time consuming to execute at commercial
scale. Our IsoTag™ technology will provide an innovative, non-chromatographic alternative that
combines affinity/phase separation with microfiltration. IsoTag™ will create a paradigm shift in
the bioprocessing industry with its lower cost and continuous process that offers faster mass
transfer, milder elution conditions, and enhanced productivity. | Q48969892 | 0.027551 | Affinity capture | 7 |
000c24e7d3b5ae3c56c9c87ad2cca4330c1f05ca | Abstract
The objective of this NIH Phase II SBIR proposal is to demonstrate the commercial feasibility of IsoTag™, a
novel cost-effective method to purify monoclonal antibodies (mAbs) that eliminates the need for Protein A (PrA)
chromatography. This objective will be achieved by using a recombinant fusion comprised of a stimulus
responsive elastin-like polypeptide (ELP) that can undergo a reversible soluble to insoluble phase transition,
and the Z-domain (ZD) derived from PrA that binds the constant region of mAbs with high affinity and
specificity. This proposal is motivated by the fact that the first and critical step of mAb purification —PrA
affinity chromatography— has not kept pace with improvements in the recombinant expression level of mAbs,
creating a bottleneck in their production. IsoTag™, which combines affinity capture of mAbs and their isolation
by triggered phase separation with microfiltration, addresses this bottleneck. Upon addition of the ELP-ZD
fusion to clarified cell culture harvest, the ELP-ZD binds the mAb. Upon triggering the phase transition of the
mAb/ELP-ZD with a small amount of kosmotropic salt, the mAb/ELP-ZD complex undergoes liquid-liquid phase
separation into micron-sized droplets, allowing it to be separated from all soluble contaminants by continuous
tangential flow filtration, Next, the pH is lowered to ~4.0, which causes the ZD to lose its affinity for the mAb.
The pure, eluted mAb is in the soluble phase and the ELP-ZD can be regenerated from the insoluble phase. In
the NIH funded Phase I of this project, we have fully optimized the ELP-ZD and the process parameters for
IsoTag™ purification. We have shown that at the bench scale, IsoTag™ can be used to successfully isolate
mAb from mammalian cell culture with yields and contaminant removal that outperform commercially available
alternatives (GE Predictor Plate and Thermo Fisher Nab Spin Column). Having established technical feasibility
and developed a research use only, bench scale product, we plan to validate IsoTag™andapos;s commercial feasibility
for large-scale mAb purification in this Phase II proposal. Our Specific Aims to achieve this objective are: (1)
We will optimize microbial production of the ELP-ZD fusion using fermentation and develop a scalable
purification process. We will then perform a 30 L pilot production run and begin developing an ISO9001 quality
control management protocol. (2) We will validate an assay for quantifying residual ELP-ZD. (3) We will
perform side-by-side purification of the NISTmAb at 30 L scale to compare IsoTag™ to leading PrA resins,
MAbSelect SuRe and Amsphere A3. Last, we will use BioSolve and Matlab software to develop a model for an
interface that takes a customerandapos;s inputs and calculates a personalized cost savings by switching to IsoTag™.
The outcome of this project will be compelling data that encourages customer conversion. Isolereandapos;s vision is
that IsoTag™ will be a plug-and-play downstream process that allows the industry to achieve fully integrated,
continuous manufacturing where improved productivity and lower cost can make mAbs globally accessible.PROJECT NARRATIVE
Monoclonal antibodies (mAb) are an important and fast growing drug class, but the first phase in
their purification process is a capture step via Protein A chromatography, which requires
expensive resin and equipment making it difficult and time consuming to execute at commercial
scale. Our IsoTag™ technology will provide an innovative, non-chromatographic alternative that
combines affinity/phase separation with microfiltration. IsoTag™ will create a paradigm shift in
the bioprocessing industry with its lower cost and continuous process that offers faster mass
transfer, milder elution conditions, and enhanced productivity. | Q170050 | 0.024699 | Chromatography | 8 |
000c24e7d3b5ae3c56c9c87ad2cca4330c1f05ca | Abstract
The objective of this NIH Phase II SBIR proposal is to demonstrate the commercial feasibility of IsoTag™, a
novel cost-effective method to purify monoclonal antibodies (mAbs) that eliminates the need for Protein A (PrA)
chromatography. This objective will be achieved by using a recombinant fusion comprised of a stimulus
responsive elastin-like polypeptide (ELP) that can undergo a reversible soluble to insoluble phase transition,
and the Z-domain (ZD) derived from PrA that binds the constant region of mAbs with high affinity and
specificity. This proposal is motivated by the fact that the first and critical step of mAb purification —PrA
affinity chromatography— has not kept pace with improvements in the recombinant expression level of mAbs,
creating a bottleneck in their production. IsoTag™, which combines affinity capture of mAbs and their isolation
by triggered phase separation with microfiltration, addresses this bottleneck. Upon addition of the ELP-ZD
fusion to clarified cell culture harvest, the ELP-ZD binds the mAb. Upon triggering the phase transition of the
mAb/ELP-ZD with a small amount of kosmotropic salt, the mAb/ELP-ZD complex undergoes liquid-liquid phase
separation into micron-sized droplets, allowing it to be separated from all soluble contaminants by continuous
tangential flow filtration, Next, the pH is lowered to ~4.0, which causes the ZD to lose its affinity for the mAb.
The pure, eluted mAb is in the soluble phase and the ELP-ZD can be regenerated from the insoluble phase. In
the NIH funded Phase I of this project, we have fully optimized the ELP-ZD and the process parameters for
IsoTag™ purification. We have shown that at the bench scale, IsoTag™ can be used to successfully isolate
mAb from mammalian cell culture with yields and contaminant removal that outperform commercially available
alternatives (GE Predictor Plate and Thermo Fisher Nab Spin Column). Having established technical feasibility
and developed a research use only, bench scale product, we plan to validate IsoTag™andapos;s commercial feasibility
for large-scale mAb purification in this Phase II proposal. Our Specific Aims to achieve this objective are: (1)
We will optimize microbial production of the ELP-ZD fusion using fermentation and develop a scalable
purification process. We will then perform a 30 L pilot production run and begin developing an ISO9001 quality
control management protocol. (2) We will validate an assay for quantifying residual ELP-ZD. (3) We will
perform side-by-side purification of the NISTmAb at 30 L scale to compare IsoTag™ to leading PrA resins,
MAbSelect SuRe and Amsphere A3. Last, we will use BioSolve and Matlab software to develop a model for an
interface that takes a customerandapos;s inputs and calculates a personalized cost savings by switching to IsoTag™.
The outcome of this project will be compelling data that encourages customer conversion. Isolereandapos;s vision is
that IsoTag™ will be a plug-and-play downstream process that allows the industry to achieve fully integrated,
continuous manufacturing where improved productivity and lower cost can make mAbs globally accessible.PROJECT NARRATIVE
Monoclonal antibodies (mAb) are an important and fast growing drug class, but the first phase in
their purification process is a capture step via Protein A chromatography, which requires
expensive resin and equipment making it difficult and time consuming to execute at commercial
scale. Our IsoTag™ technology will provide an innovative, non-chromatographic alternative that
combines affinity/phase separation with microfiltration. IsoTag™ will create a paradigm shift in
the bioprocessing industry with its lower cost and continuous process that offers faster mass
transfer, milder elution conditions, and enhanced productivity. | Q903485 | 0.024481 | Protein purification | 9 |
000c24e7d3b5ae3c56c9c87ad2cca4330c1f05ca | Abstract
The objective of this NIH Phase II SBIR proposal is to demonstrate the commercial feasibility of IsoTag™, a
novel cost-effective method to purify monoclonal antibodies (mAbs) that eliminates the need for Protein A (PrA)
chromatography. This objective will be achieved by using a recombinant fusion comprised of a stimulus
responsive elastin-like polypeptide (ELP) that can undergo a reversible soluble to insoluble phase transition,
and the Z-domain (ZD) derived from PrA that binds the constant region of mAbs with high affinity and
specificity. This proposal is motivated by the fact that the first and critical step of mAb purification —PrA
affinity chromatography— has not kept pace with improvements in the recombinant expression level of mAbs,
creating a bottleneck in their production. IsoTag™, which combines affinity capture of mAbs and their isolation
by triggered phase separation with microfiltration, addresses this bottleneck. Upon addition of the ELP-ZD
fusion to clarified cell culture harvest, the ELP-ZD binds the mAb. Upon triggering the phase transition of the
mAb/ELP-ZD with a small amount of kosmotropic salt, the mAb/ELP-ZD complex undergoes liquid-liquid phase
separation into micron-sized droplets, allowing it to be separated from all soluble contaminants by continuous
tangential flow filtration, Next, the pH is lowered to ~4.0, which causes the ZD to lose its affinity for the mAb.
The pure, eluted mAb is in the soluble phase and the ELP-ZD can be regenerated from the insoluble phase. In
the NIH funded Phase I of this project, we have fully optimized the ELP-ZD and the process parameters for
IsoTag™ purification. We have shown that at the bench scale, IsoTag™ can be used to successfully isolate
mAb from mammalian cell culture with yields and contaminant removal that outperform commercially available
alternatives (GE Predictor Plate and Thermo Fisher Nab Spin Column). Having established technical feasibility
and developed a research use only, bench scale product, we plan to validate IsoTag™andapos;s commercial feasibility
for large-scale mAb purification in this Phase II proposal. Our Specific Aims to achieve this objective are: (1)
We will optimize microbial production of the ELP-ZD fusion using fermentation and develop a scalable
purification process. We will then perform a 30 L pilot production run and begin developing an ISO9001 quality
control management protocol. (2) We will validate an assay for quantifying residual ELP-ZD. (3) We will
perform side-by-side purification of the NISTmAb at 30 L scale to compare IsoTag™ to leading PrA resins,
MAbSelect SuRe and Amsphere A3. Last, we will use BioSolve and Matlab software to develop a model for an
interface that takes a customerandapos;s inputs and calculates a personalized cost savings by switching to IsoTag™.
The outcome of this project will be compelling data that encourages customer conversion. Isolereandapos;s vision is
that IsoTag™ will be a plug-and-play downstream process that allows the industry to achieve fully integrated,
continuous manufacturing where improved productivity and lower cost can make mAbs globally accessible.PROJECT NARRATIVE
Monoclonal antibodies (mAb) are an important and fast growing drug class, but the first phase in
their purification process is a capture step via Protein A chromatography, which requires
expensive resin and equipment making it difficult and time consuming to execute at commercial
scale. Our IsoTag™ technology will provide an innovative, non-chromatographic alternative that
combines affinity/phase separation with microfiltration. IsoTag™ will create a paradigm shift in
the bioprocessing industry with its lower cost and continuous process that offers faster mass
transfer, milder elution conditions, and enhanced productivity. | Q65087614 | 0.023268 | Phase separation | 10 |
000c24e7d3b5ae3c56c9c87ad2cca4330c1f05ca | Abstract
The objective of this NIH Phase II SBIR proposal is to demonstrate the commercial feasibility of IsoTag™, a
novel cost-effective method to purify monoclonal antibodies (mAbs) that eliminates the need for Protein A (PrA)
chromatography. This objective will be achieved by using a recombinant fusion comprised of a stimulus
responsive elastin-like polypeptide (ELP) that can undergo a reversible soluble to insoluble phase transition,
and the Z-domain (ZD) derived from PrA that binds the constant region of mAbs with high affinity and
specificity. This proposal is motivated by the fact that the first and critical step of mAb purification —PrA
affinity chromatography— has not kept pace with improvements in the recombinant expression level of mAbs,
creating a bottleneck in their production. IsoTag™, which combines affinity capture of mAbs and their isolation
by triggered phase separation with microfiltration, addresses this bottleneck. Upon addition of the ELP-ZD
fusion to clarified cell culture harvest, the ELP-ZD binds the mAb. Upon triggering the phase transition of the
mAb/ELP-ZD with a small amount of kosmotropic salt, the mAb/ELP-ZD complex undergoes liquid-liquid phase
separation into micron-sized droplets, allowing it to be separated from all soluble contaminants by continuous
tangential flow filtration, Next, the pH is lowered to ~4.0, which causes the ZD to lose its affinity for the mAb.
The pure, eluted mAb is in the soluble phase and the ELP-ZD can be regenerated from the insoluble phase. In
the NIH funded Phase I of this project, we have fully optimized the ELP-ZD and the process parameters for
IsoTag™ purification. We have shown that at the bench scale, IsoTag™ can be used to successfully isolate
mAb from mammalian cell culture with yields and contaminant removal that outperform commercially available
alternatives (GE Predictor Plate and Thermo Fisher Nab Spin Column). Having established technical feasibility
and developed a research use only, bench scale product, we plan to validate IsoTag™andapos;s commercial feasibility
for large-scale mAb purification in this Phase II proposal. Our Specific Aims to achieve this objective are: (1)
We will optimize microbial production of the ELP-ZD fusion using fermentation and develop a scalable
purification process. We will then perform a 30 L pilot production run and begin developing an ISO9001 quality
control management protocol. (2) We will validate an assay for quantifying residual ELP-ZD. (3) We will
perform side-by-side purification of the NISTmAb at 30 L scale to compare IsoTag™ to leading PrA resins,
MAbSelect SuRe and Amsphere A3. Last, we will use BioSolve and Matlab software to develop a model for an
interface that takes a customerandapos;s inputs and calculates a personalized cost savings by switching to IsoTag™.
The outcome of this project will be compelling data that encourages customer conversion. Isolereandapos;s vision is
that IsoTag™ will be a plug-and-play downstream process that allows the industry to achieve fully integrated,
continuous manufacturing where improved productivity and lower cost can make mAbs globally accessible.PROJECT NARRATIVE
Monoclonal antibodies (mAb) are an important and fast growing drug class, but the first phase in
their purification process is a capture step via Protein A chromatography, which requires
expensive resin and equipment making it difficult and time consuming to execute at commercial
scale. Our IsoTag™ technology will provide an innovative, non-chromatographic alternative that
combines affinity/phase separation with microfiltration. IsoTag™ will create a paradigm shift in
the bioprocessing industry with its lower cost and continuous process that offers faster mass
transfer, milder elution conditions, and enhanced productivity. | Q2111958 | 0.021785 | Productivity | 11 |
000c24e7d3b5ae3c56c9c87ad2cca4330c1f05ca | Abstract
The objective of this NIH Phase II SBIR proposal is to demonstrate the commercial feasibility of IsoTag™, a
novel cost-effective method to purify monoclonal antibodies (mAbs) that eliminates the need for Protein A (PrA)
chromatography. This objective will be achieved by using a recombinant fusion comprised of a stimulus
responsive elastin-like polypeptide (ELP) that can undergo a reversible soluble to insoluble phase transition,
and the Z-domain (ZD) derived from PrA that binds the constant region of mAbs with high affinity and
specificity. This proposal is motivated by the fact that the first and critical step of mAb purification —PrA
affinity chromatography— has not kept pace with improvements in the recombinant expression level of mAbs,
creating a bottleneck in their production. IsoTag™, which combines affinity capture of mAbs and their isolation
by triggered phase separation with microfiltration, addresses this bottleneck. Upon addition of the ELP-ZD
fusion to clarified cell culture harvest, the ELP-ZD binds the mAb. Upon triggering the phase transition of the
mAb/ELP-ZD with a small amount of kosmotropic salt, the mAb/ELP-ZD complex undergoes liquid-liquid phase
separation into micron-sized droplets, allowing it to be separated from all soluble contaminants by continuous
tangential flow filtration, Next, the pH is lowered to ~4.0, which causes the ZD to lose its affinity for the mAb.
The pure, eluted mAb is in the soluble phase and the ELP-ZD can be regenerated from the insoluble phase. In
the NIH funded Phase I of this project, we have fully optimized the ELP-ZD and the process parameters for
IsoTag™ purification. We have shown that at the bench scale, IsoTag™ can be used to successfully isolate
mAb from mammalian cell culture with yields and contaminant removal that outperform commercially available
alternatives (GE Predictor Plate and Thermo Fisher Nab Spin Column). Having established technical feasibility
and developed a research use only, bench scale product, we plan to validate IsoTag™andapos;s commercial feasibility
for large-scale mAb purification in this Phase II proposal. Our Specific Aims to achieve this objective are: (1)
We will optimize microbial production of the ELP-ZD fusion using fermentation and develop a scalable
purification process. We will then perform a 30 L pilot production run and begin developing an ISO9001 quality
control management protocol. (2) We will validate an assay for quantifying residual ELP-ZD. (3) We will
perform side-by-side purification of the NISTmAb at 30 L scale to compare IsoTag™ to leading PrA resins,
MAbSelect SuRe and Amsphere A3. Last, we will use BioSolve and Matlab software to develop a model for an
interface that takes a customerandapos;s inputs and calculates a personalized cost savings by switching to IsoTag™.
The outcome of this project will be compelling data that encourages customer conversion. Isolereandapos;s vision is
that IsoTag™ will be a plug-and-play downstream process that allows the industry to achieve fully integrated,
continuous manufacturing where improved productivity and lower cost can make mAbs globally accessible.PROJECT NARRATIVE
Monoclonal antibodies (mAb) are an important and fast growing drug class, but the first phase in
their purification process is a capture step via Protein A chromatography, which requires
expensive resin and equipment making it difficult and time consuming to execute at commercial
scale. Our IsoTag™ technology will provide an innovative, non-chromatographic alternative that
combines affinity/phase separation with microfiltration. IsoTag™ will create a paradigm shift in
the bioprocessing industry with its lower cost and continuous process that offers faster mass
transfer, milder elution conditions, and enhanced productivity. | Q185357 | 0.021394 | Phase transition | 12 |
000c24e7d3b5ae3c56c9c87ad2cca4330c1f05ca | Abstract
The objective of this NIH Phase II SBIR proposal is to demonstrate the commercial feasibility of IsoTag™, a
novel cost-effective method to purify monoclonal antibodies (mAbs) that eliminates the need for Protein A (PrA)
chromatography. This objective will be achieved by using a recombinant fusion comprised of a stimulus
responsive elastin-like polypeptide (ELP) that can undergo a reversible soluble to insoluble phase transition,
and the Z-domain (ZD) derived from PrA that binds the constant region of mAbs with high affinity and
specificity. This proposal is motivated by the fact that the first and critical step of mAb purification —PrA
affinity chromatography— has not kept pace with improvements in the recombinant expression level of mAbs,
creating a bottleneck in their production. IsoTag™, which combines affinity capture of mAbs and their isolation
by triggered phase separation with microfiltration, addresses this bottleneck. Upon addition of the ELP-ZD
fusion to clarified cell culture harvest, the ELP-ZD binds the mAb. Upon triggering the phase transition of the
mAb/ELP-ZD with a small amount of kosmotropic salt, the mAb/ELP-ZD complex undergoes liquid-liquid phase
separation into micron-sized droplets, allowing it to be separated from all soluble contaminants by continuous
tangential flow filtration, Next, the pH is lowered to ~4.0, which causes the ZD to lose its affinity for the mAb.
The pure, eluted mAb is in the soluble phase and the ELP-ZD can be regenerated from the insoluble phase. In
the NIH funded Phase I of this project, we have fully optimized the ELP-ZD and the process parameters for
IsoTag™ purification. We have shown that at the bench scale, IsoTag™ can be used to successfully isolate
mAb from mammalian cell culture with yields and contaminant removal that outperform commercially available
alternatives (GE Predictor Plate and Thermo Fisher Nab Spin Column). Having established technical feasibility
and developed a research use only, bench scale product, we plan to validate IsoTag™andapos;s commercial feasibility
for large-scale mAb purification in this Phase II proposal. Our Specific Aims to achieve this objective are: (1)
We will optimize microbial production of the ELP-ZD fusion using fermentation and develop a scalable
purification process. We will then perform a 30 L pilot production run and begin developing an ISO9001 quality
control management protocol. (2) We will validate an assay for quantifying residual ELP-ZD. (3) We will
perform side-by-side purification of the NISTmAb at 30 L scale to compare IsoTag™ to leading PrA resins,
MAbSelect SuRe and Amsphere A3. Last, we will use BioSolve and Matlab software to develop a model for an
interface that takes a customerandapos;s inputs and calculates a personalized cost savings by switching to IsoTag™.
The outcome of this project will be compelling data that encourages customer conversion. Isolereandapos;s vision is
that IsoTag™ will be a plug-and-play downstream process that allows the industry to achieve fully integrated,
continuous manufacturing where improved productivity and lower cost can make mAbs globally accessible.PROJECT NARRATIVE
Monoclonal antibodies (mAb) are an important and fast growing drug class, but the first phase in
their purification process is a capture step via Protein A chromatography, which requires
expensive resin and equipment making it difficult and time consuming to execute at commercial
scale. Our IsoTag™ technology will provide an innovative, non-chromatographic alternative that
combines affinity/phase separation with microfiltration. IsoTag™ will create a paradigm shift in
the bioprocessing industry with its lower cost and continuous process that offers faster mass
transfer, milder elution conditions, and enhanced productivity. | Q905749 | 0.020991 | Ion chromatography | 13 |
000c24e7d3b5ae3c56c9c87ad2cca4330c1f05ca | Abstract
The objective of this NIH Phase II SBIR proposal is to demonstrate the commercial feasibility of IsoTag™, a
novel cost-effective method to purify monoclonal antibodies (mAbs) that eliminates the need for Protein A (PrA)
chromatography. This objective will be achieved by using a recombinant fusion comprised of a stimulus
responsive elastin-like polypeptide (ELP) that can undergo a reversible soluble to insoluble phase transition,
and the Z-domain (ZD) derived from PrA that binds the constant region of mAbs with high affinity and
specificity. This proposal is motivated by the fact that the first and critical step of mAb purification —PrA
affinity chromatography— has not kept pace with improvements in the recombinant expression level of mAbs,
creating a bottleneck in their production. IsoTag™, which combines affinity capture of mAbs and their isolation
by triggered phase separation with microfiltration, addresses this bottleneck. Upon addition of the ELP-ZD
fusion to clarified cell culture harvest, the ELP-ZD binds the mAb. Upon triggering the phase transition of the
mAb/ELP-ZD with a small amount of kosmotropic salt, the mAb/ELP-ZD complex undergoes liquid-liquid phase
separation into micron-sized droplets, allowing it to be separated from all soluble contaminants by continuous
tangential flow filtration, Next, the pH is lowered to ~4.0, which causes the ZD to lose its affinity for the mAb.
The pure, eluted mAb is in the soluble phase and the ELP-ZD can be regenerated from the insoluble phase. In
the NIH funded Phase I of this project, we have fully optimized the ELP-ZD and the process parameters for
IsoTag™ purification. We have shown that at the bench scale, IsoTag™ can be used to successfully isolate
mAb from mammalian cell culture with yields and contaminant removal that outperform commercially available
alternatives (GE Predictor Plate and Thermo Fisher Nab Spin Column). Having established technical feasibility
and developed a research use only, bench scale product, we plan to validate IsoTag™andapos;s commercial feasibility
for large-scale mAb purification in this Phase II proposal. Our Specific Aims to achieve this objective are: (1)
We will optimize microbial production of the ELP-ZD fusion using fermentation and develop a scalable
purification process. We will then perform a 30 L pilot production run and begin developing an ISO9001 quality
control management protocol. (2) We will validate an assay for quantifying residual ELP-ZD. (3) We will
perform side-by-side purification of the NISTmAb at 30 L scale to compare IsoTag™ to leading PrA resins,
MAbSelect SuRe and Amsphere A3. Last, we will use BioSolve and Matlab software to develop a model for an
interface that takes a customerandapos;s inputs and calculates a personalized cost savings by switching to IsoTag™.
The outcome of this project will be compelling data that encourages customer conversion. Isolereandapos;s vision is
that IsoTag™ will be a plug-and-play downstream process that allows the industry to achieve fully integrated,
continuous manufacturing where improved productivity and lower cost can make mAbs globally accessible.PROJECT NARRATIVE
Monoclonal antibodies (mAb) are an important and fast growing drug class, but the first phase in
their purification process is a capture step via Protein A chromatography, which requires
expensive resin and equipment making it difficult and time consuming to execute at commercial
scale. Our IsoTag™ technology will provide an innovative, non-chromatographic alternative that
combines affinity/phase separation with microfiltration. IsoTag™ will create a paradigm shift in
the bioprocessing industry with its lower cost and continuous process that offers faster mass
transfer, milder elution conditions, and enhanced productivity. | Q827792 | 0.020552 | Quality control | 14 |
000c24e7d3b5ae3c56c9c87ad2cca4330c1f05ca | Abstract
The objective of this NIH Phase II SBIR proposal is to demonstrate the commercial feasibility of IsoTag™, a
novel cost-effective method to purify monoclonal antibodies (mAbs) that eliminates the need for Protein A (PrA)
chromatography. This objective will be achieved by using a recombinant fusion comprised of a stimulus
responsive elastin-like polypeptide (ELP) that can undergo a reversible soluble to insoluble phase transition,
and the Z-domain (ZD) derived from PrA that binds the constant region of mAbs with high affinity and
specificity. This proposal is motivated by the fact that the first and critical step of mAb purification —PrA
affinity chromatography— has not kept pace with improvements in the recombinant expression level of mAbs,
creating a bottleneck in their production. IsoTag™, which combines affinity capture of mAbs and their isolation
by triggered phase separation with microfiltration, addresses this bottleneck. Upon addition of the ELP-ZD
fusion to clarified cell culture harvest, the ELP-ZD binds the mAb. Upon triggering the phase transition of the
mAb/ELP-ZD with a small amount of kosmotropic salt, the mAb/ELP-ZD complex undergoes liquid-liquid phase
separation into micron-sized droplets, allowing it to be separated from all soluble contaminants by continuous
tangential flow filtration, Next, the pH is lowered to ~4.0, which causes the ZD to lose its affinity for the mAb.
The pure, eluted mAb is in the soluble phase and the ELP-ZD can be regenerated from the insoluble phase. In
the NIH funded Phase I of this project, we have fully optimized the ELP-ZD and the process parameters for
IsoTag™ purification. We have shown that at the bench scale, IsoTag™ can be used to successfully isolate
mAb from mammalian cell culture with yields and contaminant removal that outperform commercially available
alternatives (GE Predictor Plate and Thermo Fisher Nab Spin Column). Having established technical feasibility
and developed a research use only, bench scale product, we plan to validate IsoTag™andapos;s commercial feasibility
for large-scale mAb purification in this Phase II proposal. Our Specific Aims to achieve this objective are: (1)
We will optimize microbial production of the ELP-ZD fusion using fermentation and develop a scalable
purification process. We will then perform a 30 L pilot production run and begin developing an ISO9001 quality
control management protocol. (2) We will validate an assay for quantifying residual ELP-ZD. (3) We will
perform side-by-side purification of the NISTmAb at 30 L scale to compare IsoTag™ to leading PrA resins,
MAbSelect SuRe and Amsphere A3. Last, we will use BioSolve and Matlab software to develop a model for an
interface that takes a customerandapos;s inputs and calculates a personalized cost savings by switching to IsoTag™.
The outcome of this project will be compelling data that encourages customer conversion. Isolereandapos;s vision is
that IsoTag™ will be a plug-and-play downstream process that allows the industry to achieve fully integrated,
continuous manufacturing where improved productivity and lower cost can make mAbs globally accessible.PROJECT NARRATIVE
Monoclonal antibodies (mAb) are an important and fast growing drug class, but the first phase in
their purification process is a capture step via Protein A chromatography, which requires
expensive resin and equipment making it difficult and time consuming to execute at commercial
scale. Our IsoTag™ technology will provide an innovative, non-chromatographic alternative that
combines affinity/phase separation with microfiltration. IsoTag™ will create a paradigm shift in
the bioprocessing industry with its lower cost and continuous process that offers faster mass
transfer, milder elution conditions, and enhanced productivity. | Q7248508 | 0.020085 | Programming productivity | 15 |
000c24e7d3b5ae3c56c9c87ad2cca4330c1f05ca | Abstract
The objective of this NIH Phase II SBIR proposal is to demonstrate the commercial feasibility of IsoTag™, a
novel cost-effective method to purify monoclonal antibodies (mAbs) that eliminates the need for Protein A (PrA)
chromatography. This objective will be achieved by using a recombinant fusion comprised of a stimulus
responsive elastin-like polypeptide (ELP) that can undergo a reversible soluble to insoluble phase transition,
and the Z-domain (ZD) derived from PrA that binds the constant region of mAbs with high affinity and
specificity. This proposal is motivated by the fact that the first and critical step of mAb purification —PrA
affinity chromatography— has not kept pace with improvements in the recombinant expression level of mAbs,
creating a bottleneck in their production. IsoTag™, which combines affinity capture of mAbs and their isolation
by triggered phase separation with microfiltration, addresses this bottleneck. Upon addition of the ELP-ZD
fusion to clarified cell culture harvest, the ELP-ZD binds the mAb. Upon triggering the phase transition of the
mAb/ELP-ZD with a small amount of kosmotropic salt, the mAb/ELP-ZD complex undergoes liquid-liquid phase
separation into micron-sized droplets, allowing it to be separated from all soluble contaminants by continuous
tangential flow filtration, Next, the pH is lowered to ~4.0, which causes the ZD to lose its affinity for the mAb.
The pure, eluted mAb is in the soluble phase and the ELP-ZD can be regenerated from the insoluble phase. In
the NIH funded Phase I of this project, we have fully optimized the ELP-ZD and the process parameters for
IsoTag™ purification. We have shown that at the bench scale, IsoTag™ can be used to successfully isolate
mAb from mammalian cell culture with yields and contaminant removal that outperform commercially available
alternatives (GE Predictor Plate and Thermo Fisher Nab Spin Column). Having established technical feasibility
and developed a research use only, bench scale product, we plan to validate IsoTag™andapos;s commercial feasibility
for large-scale mAb purification in this Phase II proposal. Our Specific Aims to achieve this objective are: (1)
We will optimize microbial production of the ELP-ZD fusion using fermentation and develop a scalable
purification process. We will then perform a 30 L pilot production run and begin developing an ISO9001 quality
control management protocol. (2) We will validate an assay for quantifying residual ELP-ZD. (3) We will
perform side-by-side purification of the NISTmAb at 30 L scale to compare IsoTag™ to leading PrA resins,
MAbSelect SuRe and Amsphere A3. Last, we will use BioSolve and Matlab software to develop a model for an
interface that takes a customerandapos;s inputs and calculates a personalized cost savings by switching to IsoTag™.
The outcome of this project will be compelling data that encourages customer conversion. Isolereandapos;s vision is
that IsoTag™ will be a plug-and-play downstream process that allows the industry to achieve fully integrated,
continuous manufacturing where improved productivity and lower cost can make mAbs globally accessible.PROJECT NARRATIVE
Monoclonal antibodies (mAb) are an important and fast growing drug class, but the first phase in
their purification process is a capture step via Protein A chromatography, which requires
expensive resin and equipment making it difficult and time consuming to execute at commercial
scale. Our IsoTag™ technology will provide an innovative, non-chromatographic alternative that
combines affinity/phase separation with microfiltration. IsoTag™ will create a paradigm shift in
the bioprocessing industry with its lower cost and continuous process that offers faster mass
transfer, milder elution conditions, and enhanced productivity. | Q271580 | 0.018078 | Electron affinity | 16 |
000c24e7d3b5ae3c56c9c87ad2cca4330c1f05ca | Abstract
The objective of this NIH Phase II SBIR proposal is to demonstrate the commercial feasibility of IsoTag™, a
novel cost-effective method to purify monoclonal antibodies (mAbs) that eliminates the need for Protein A (PrA)
chromatography. This objective will be achieved by using a recombinant fusion comprised of a stimulus
responsive elastin-like polypeptide (ELP) that can undergo a reversible soluble to insoluble phase transition,
and the Z-domain (ZD) derived from PrA that binds the constant region of mAbs with high affinity and
specificity. This proposal is motivated by the fact that the first and critical step of mAb purification —PrA
affinity chromatography— has not kept pace with improvements in the recombinant expression level of mAbs,
creating a bottleneck in their production. IsoTag™, which combines affinity capture of mAbs and their isolation
by triggered phase separation with microfiltration, addresses this bottleneck. Upon addition of the ELP-ZD
fusion to clarified cell culture harvest, the ELP-ZD binds the mAb. Upon triggering the phase transition of the
mAb/ELP-ZD with a small amount of kosmotropic salt, the mAb/ELP-ZD complex undergoes liquid-liquid phase
separation into micron-sized droplets, allowing it to be separated from all soluble contaminants by continuous
tangential flow filtration, Next, the pH is lowered to ~4.0, which causes the ZD to lose its affinity for the mAb.
The pure, eluted mAb is in the soluble phase and the ELP-ZD can be regenerated from the insoluble phase. In
the NIH funded Phase I of this project, we have fully optimized the ELP-ZD and the process parameters for
IsoTag™ purification. We have shown that at the bench scale, IsoTag™ can be used to successfully isolate
mAb from mammalian cell culture with yields and contaminant removal that outperform commercially available
alternatives (GE Predictor Plate and Thermo Fisher Nab Spin Column). Having established technical feasibility
and developed a research use only, bench scale product, we plan to validate IsoTag™andapos;s commercial feasibility
for large-scale mAb purification in this Phase II proposal. Our Specific Aims to achieve this objective are: (1)
We will optimize microbial production of the ELP-ZD fusion using fermentation and develop a scalable
purification process. We will then perform a 30 L pilot production run and begin developing an ISO9001 quality
control management protocol. (2) We will validate an assay for quantifying residual ELP-ZD. (3) We will
perform side-by-side purification of the NISTmAb at 30 L scale to compare IsoTag™ to leading PrA resins,
MAbSelect SuRe and Amsphere A3. Last, we will use BioSolve and Matlab software to develop a model for an
interface that takes a customerandapos;s inputs and calculates a personalized cost savings by switching to IsoTag™.
The outcome of this project will be compelling data that encourages customer conversion. Isolereandapos;s vision is
that IsoTag™ will be a plug-and-play downstream process that allows the industry to achieve fully integrated,
continuous manufacturing where improved productivity and lower cost can make mAbs globally accessible.PROJECT NARRATIVE
Monoclonal antibodies (mAb) are an important and fast growing drug class, but the first phase in
their purification process is a capture step via Protein A chromatography, which requires
expensive resin and equipment making it difficult and time consuming to execute at commercial
scale. Our IsoTag™ technology will provide an innovative, non-chromatographic alternative that
combines affinity/phase separation with microfiltration. IsoTag™ will create a paradigm shift in
the bioprocessing industry with its lower cost and continuous process that offers faster mass
transfer, milder elution conditions, and enhanced productivity. | Q906963 | 0.018074 | Resin casting | 17 |
000c24e7d3b5ae3c56c9c87ad2cca4330c1f05ca | Abstract
The objective of this NIH Phase II SBIR proposal is to demonstrate the commercial feasibility of IsoTag™, a
novel cost-effective method to purify monoclonal antibodies (mAbs) that eliminates the need for Protein A (PrA)
chromatography. This objective will be achieved by using a recombinant fusion comprised of a stimulus
responsive elastin-like polypeptide (ELP) that can undergo a reversible soluble to insoluble phase transition,
and the Z-domain (ZD) derived from PrA that binds the constant region of mAbs with high affinity and
specificity. This proposal is motivated by the fact that the first and critical step of mAb purification —PrA
affinity chromatography— has not kept pace with improvements in the recombinant expression level of mAbs,
creating a bottleneck in their production. IsoTag™, which combines affinity capture of mAbs and their isolation
by triggered phase separation with microfiltration, addresses this bottleneck. Upon addition of the ELP-ZD
fusion to clarified cell culture harvest, the ELP-ZD binds the mAb. Upon triggering the phase transition of the
mAb/ELP-ZD with a small amount of kosmotropic salt, the mAb/ELP-ZD complex undergoes liquid-liquid phase
separation into micron-sized droplets, allowing it to be separated from all soluble contaminants by continuous
tangential flow filtration, Next, the pH is lowered to ~4.0, which causes the ZD to lose its affinity for the mAb.
The pure, eluted mAb is in the soluble phase and the ELP-ZD can be regenerated from the insoluble phase. In
the NIH funded Phase I of this project, we have fully optimized the ELP-ZD and the process parameters for
IsoTag™ purification. We have shown that at the bench scale, IsoTag™ can be used to successfully isolate
mAb from mammalian cell culture with yields and contaminant removal that outperform commercially available
alternatives (GE Predictor Plate and Thermo Fisher Nab Spin Column). Having established technical feasibility
and developed a research use only, bench scale product, we plan to validate IsoTag™andapos;s commercial feasibility
for large-scale mAb purification in this Phase II proposal. Our Specific Aims to achieve this objective are: (1)
We will optimize microbial production of the ELP-ZD fusion using fermentation and develop a scalable
purification process. We will then perform a 30 L pilot production run and begin developing an ISO9001 quality
control management protocol. (2) We will validate an assay for quantifying residual ELP-ZD. (3) We will
perform side-by-side purification of the NISTmAb at 30 L scale to compare IsoTag™ to leading PrA resins,
MAbSelect SuRe and Amsphere A3. Last, we will use BioSolve and Matlab software to develop a model for an
interface that takes a customerandapos;s inputs and calculates a personalized cost savings by switching to IsoTag™.
The outcome of this project will be compelling data that encourages customer conversion. Isolereandapos;s vision is
that IsoTag™ will be a plug-and-play downstream process that allows the industry to achieve fully integrated,
continuous manufacturing where improved productivity and lower cost can make mAbs globally accessible.PROJECT NARRATIVE
Monoclonal antibodies (mAb) are an important and fast growing drug class, but the first phase in
their purification process is a capture step via Protein A chromatography, which requires
expensive resin and equipment making it difficult and time consuming to execute at commercial
scale. Our IsoTag™ technology will provide an innovative, non-chromatographic alternative that
combines affinity/phase separation with microfiltration. IsoTag™ will create a paradigm shift in
the bioprocessing industry with its lower cost and continuous process that offers faster mass
transfer, milder elution conditions, and enhanced productivity. | Q2079858 | 0.016826 | Side-by-side (vehicle) | 18 |
000c24e7d3b5ae3c56c9c87ad2cca4330c1f05ca | Abstract
The objective of this NIH Phase II SBIR proposal is to demonstrate the commercial feasibility of IsoTag™, a
novel cost-effective method to purify monoclonal antibodies (mAbs) that eliminates the need for Protein A (PrA)
chromatography. This objective will be achieved by using a recombinant fusion comprised of a stimulus
responsive elastin-like polypeptide (ELP) that can undergo a reversible soluble to insoluble phase transition,
and the Z-domain (ZD) derived from PrA that binds the constant region of mAbs with high affinity and
specificity. This proposal is motivated by the fact that the first and critical step of mAb purification —PrA
affinity chromatography— has not kept pace with improvements in the recombinant expression level of mAbs,
creating a bottleneck in their production. IsoTag™, which combines affinity capture of mAbs and their isolation
by triggered phase separation with microfiltration, addresses this bottleneck. Upon addition of the ELP-ZD
fusion to clarified cell culture harvest, the ELP-ZD binds the mAb. Upon triggering the phase transition of the
mAb/ELP-ZD with a small amount of kosmotropic salt, the mAb/ELP-ZD complex undergoes liquid-liquid phase
separation into micron-sized droplets, allowing it to be separated from all soluble contaminants by continuous
tangential flow filtration, Next, the pH is lowered to ~4.0, which causes the ZD to lose its affinity for the mAb.
The pure, eluted mAb is in the soluble phase and the ELP-ZD can be regenerated from the insoluble phase. In
the NIH funded Phase I of this project, we have fully optimized the ELP-ZD and the process parameters for
IsoTag™ purification. We have shown that at the bench scale, IsoTag™ can be used to successfully isolate
mAb from mammalian cell culture with yields and contaminant removal that outperform commercially available
alternatives (GE Predictor Plate and Thermo Fisher Nab Spin Column). Having established technical feasibility
and developed a research use only, bench scale product, we plan to validate IsoTag™andapos;s commercial feasibility
for large-scale mAb purification in this Phase II proposal. Our Specific Aims to achieve this objective are: (1)
We will optimize microbial production of the ELP-ZD fusion using fermentation and develop a scalable
purification process. We will then perform a 30 L pilot production run and begin developing an ISO9001 quality
control management protocol. (2) We will validate an assay for quantifying residual ELP-ZD. (3) We will
perform side-by-side purification of the NISTmAb at 30 L scale to compare IsoTag™ to leading PrA resins,
MAbSelect SuRe and Amsphere A3. Last, we will use BioSolve and Matlab software to develop a model for an
interface that takes a customerandapos;s inputs and calculates a personalized cost savings by switching to IsoTag™.
The outcome of this project will be compelling data that encourages customer conversion. Isolereandapos;s vision is
that IsoTag™ will be a plug-and-play downstream process that allows the industry to achieve fully integrated,
continuous manufacturing where improved productivity and lower cost can make mAbs globally accessible.PROJECT NARRATIVE
Monoclonal antibodies (mAb) are an important and fast growing drug class, but the first phase in
their purification process is a capture step via Protein A chromatography, which requires
expensive resin and equipment making it difficult and time consuming to execute at commercial
scale. Our IsoTag™ technology will provide an innovative, non-chromatographic alternative that
combines affinity/phase separation with microfiltration. IsoTag™ will create a paradigm shift in
the bioprocessing industry with its lower cost and continuous process that offers faster mass
transfer, milder elution conditions, and enhanced productivity. | Q422248 | 0.016572 | Monoclonal antibody | 19 |
000c24e7d3b5ae3c56c9c87ad2cca4330c1f05ca | Abstract
The objective of this NIH Phase II SBIR proposal is to demonstrate the commercial feasibility of IsoTag™, a
novel cost-effective method to purify monoclonal antibodies (mAbs) that eliminates the need for Protein A (PrA)
chromatography. This objective will be achieved by using a recombinant fusion comprised of a stimulus
responsive elastin-like polypeptide (ELP) that can undergo a reversible soluble to insoluble phase transition,
and the Z-domain (ZD) derived from PrA that binds the constant region of mAbs with high affinity and
specificity. This proposal is motivated by the fact that the first and critical step of mAb purification —PrA
affinity chromatography— has not kept pace with improvements in the recombinant expression level of mAbs,
creating a bottleneck in their production. IsoTag™, which combines affinity capture of mAbs and their isolation
by triggered phase separation with microfiltration, addresses this bottleneck. Upon addition of the ELP-ZD
fusion to clarified cell culture harvest, the ELP-ZD binds the mAb. Upon triggering the phase transition of the
mAb/ELP-ZD with a small amount of kosmotropic salt, the mAb/ELP-ZD complex undergoes liquid-liquid phase
separation into micron-sized droplets, allowing it to be separated from all soluble contaminants by continuous
tangential flow filtration, Next, the pH is lowered to ~4.0, which causes the ZD to lose its affinity for the mAb.
The pure, eluted mAb is in the soluble phase and the ELP-ZD can be regenerated from the insoluble phase. In
the NIH funded Phase I of this project, we have fully optimized the ELP-ZD and the process parameters for
IsoTag™ purification. We have shown that at the bench scale, IsoTag™ can be used to successfully isolate
mAb from mammalian cell culture with yields and contaminant removal that outperform commercially available
alternatives (GE Predictor Plate and Thermo Fisher Nab Spin Column). Having established technical feasibility
and developed a research use only, bench scale product, we plan to validate IsoTag™andapos;s commercial feasibility
for large-scale mAb purification in this Phase II proposal. Our Specific Aims to achieve this objective are: (1)
We will optimize microbial production of the ELP-ZD fusion using fermentation and develop a scalable
purification process. We will then perform a 30 L pilot production run and begin developing an ISO9001 quality
control management protocol. (2) We will validate an assay for quantifying residual ELP-ZD. (3) We will
perform side-by-side purification of the NISTmAb at 30 L scale to compare IsoTag™ to leading PrA resins,
MAbSelect SuRe and Amsphere A3. Last, we will use BioSolve and Matlab software to develop a model for an
interface that takes a customerandapos;s inputs and calculates a personalized cost savings by switching to IsoTag™.
The outcome of this project will be compelling data that encourages customer conversion. Isolereandapos;s vision is
that IsoTag™ will be a plug-and-play downstream process that allows the industry to achieve fully integrated,
continuous manufacturing where improved productivity and lower cost can make mAbs globally accessible.PROJECT NARRATIVE
Monoclonal antibodies (mAb) are an important and fast growing drug class, but the first phase in
their purification process is a capture step via Protein A chromatography, which requires
expensive resin and equipment making it difficult and time consuming to execute at commercial
scale. Our IsoTag™ technology will provide an innovative, non-chromatographic alternative that
combines affinity/phase separation with microfiltration. IsoTag™ will create a paradigm shift in
the bioprocessing industry with its lower cost and continuous process that offers faster mass
transfer, milder elution conditions, and enhanced productivity. | Q3816336 | 0.016216 | Agricultural productivity | 20 |
000c24e7d3b5ae3c56c9c87ad2cca4330c1f05ca | Abstract
The objective of this NIH Phase II SBIR proposal is to demonstrate the commercial feasibility of IsoTag™, a
novel cost-effective method to purify monoclonal antibodies (mAbs) that eliminates the need for Protein A (PrA)
chromatography. This objective will be achieved by using a recombinant fusion comprised of a stimulus
responsive elastin-like polypeptide (ELP) that can undergo a reversible soluble to insoluble phase transition,
and the Z-domain (ZD) derived from PrA that binds the constant region of mAbs with high affinity and
specificity. This proposal is motivated by the fact that the first and critical step of mAb purification —PrA
affinity chromatography— has not kept pace with improvements in the recombinant expression level of mAbs,
creating a bottleneck in their production. IsoTag™, which combines affinity capture of mAbs and their isolation
by triggered phase separation with microfiltration, addresses this bottleneck. Upon addition of the ELP-ZD
fusion to clarified cell culture harvest, the ELP-ZD binds the mAb. Upon triggering the phase transition of the
mAb/ELP-ZD with a small amount of kosmotropic salt, the mAb/ELP-ZD complex undergoes liquid-liquid phase
separation into micron-sized droplets, allowing it to be separated from all soluble contaminants by continuous
tangential flow filtration, Next, the pH is lowered to ~4.0, which causes the ZD to lose its affinity for the mAb.
The pure, eluted mAb is in the soluble phase and the ELP-ZD can be regenerated from the insoluble phase. In
the NIH funded Phase I of this project, we have fully optimized the ELP-ZD and the process parameters for
IsoTag™ purification. We have shown that at the bench scale, IsoTag™ can be used to successfully isolate
mAb from mammalian cell culture with yields and contaminant removal that outperform commercially available
alternatives (GE Predictor Plate and Thermo Fisher Nab Spin Column). Having established technical feasibility
and developed a research use only, bench scale product, we plan to validate IsoTag™andapos;s commercial feasibility
for large-scale mAb purification in this Phase II proposal. Our Specific Aims to achieve this objective are: (1)
We will optimize microbial production of the ELP-ZD fusion using fermentation and develop a scalable
purification process. We will then perform a 30 L pilot production run and begin developing an ISO9001 quality
control management protocol. (2) We will validate an assay for quantifying residual ELP-ZD. (3) We will
perform side-by-side purification of the NISTmAb at 30 L scale to compare IsoTag™ to leading PrA resins,
MAbSelect SuRe and Amsphere A3. Last, we will use BioSolve and Matlab software to develop a model for an
interface that takes a customerandapos;s inputs and calculates a personalized cost savings by switching to IsoTag™.
The outcome of this project will be compelling data that encourages customer conversion. Isolereandapos;s vision is
that IsoTag™ will be a plug-and-play downstream process that allows the industry to achieve fully integrated,
continuous manufacturing where improved productivity and lower cost can make mAbs globally accessible.PROJECT NARRATIVE
Monoclonal antibodies (mAb) are an important and fast growing drug class, but the first phase in
their purification process is a capture step via Protein A chromatography, which requires
expensive resin and equipment making it difficult and time consuming to execute at commercial
scale. Our IsoTag™ technology will provide an innovative, non-chromatographic alternative that
combines affinity/phase separation with microfiltration. IsoTag™ will create a paradigm shift in
the bioprocessing industry with its lower cost and continuous process that offers faster mass
transfer, milder elution conditions, and enhanced productivity. | Q628895 | 0.016127 | Workforce productivity | 21 |
000c24e7d3b5ae3c56c9c87ad2cca4330c1f05ca | Abstract
The objective of this NIH Phase II SBIR proposal is to demonstrate the commercial feasibility of IsoTag™, a
novel cost-effective method to purify monoclonal antibodies (mAbs) that eliminates the need for Protein A (PrA)
chromatography. This objective will be achieved by using a recombinant fusion comprised of a stimulus
responsive elastin-like polypeptide (ELP) that can undergo a reversible soluble to insoluble phase transition,
and the Z-domain (ZD) derived from PrA that binds the constant region of mAbs with high affinity and
specificity. This proposal is motivated by the fact that the first and critical step of mAb purification —PrA
affinity chromatography— has not kept pace with improvements in the recombinant expression level of mAbs,
creating a bottleneck in their production. IsoTag™, which combines affinity capture of mAbs and their isolation
by triggered phase separation with microfiltration, addresses this bottleneck. Upon addition of the ELP-ZD
fusion to clarified cell culture harvest, the ELP-ZD binds the mAb. Upon triggering the phase transition of the
mAb/ELP-ZD with a small amount of kosmotropic salt, the mAb/ELP-ZD complex undergoes liquid-liquid phase
separation into micron-sized droplets, allowing it to be separated from all soluble contaminants by continuous
tangential flow filtration, Next, the pH is lowered to ~4.0, which causes the ZD to lose its affinity for the mAb.
The pure, eluted mAb is in the soluble phase and the ELP-ZD can be regenerated from the insoluble phase. In
the NIH funded Phase I of this project, we have fully optimized the ELP-ZD and the process parameters for
IsoTag™ purification. We have shown that at the bench scale, IsoTag™ can be used to successfully isolate
mAb from mammalian cell culture with yields and contaminant removal that outperform commercially available
alternatives (GE Predictor Plate and Thermo Fisher Nab Spin Column). Having established technical feasibility
and developed a research use only, bench scale product, we plan to validate IsoTag™andapos;s commercial feasibility
for large-scale mAb purification in this Phase II proposal. Our Specific Aims to achieve this objective are: (1)
We will optimize microbial production of the ELP-ZD fusion using fermentation and develop a scalable
purification process. We will then perform a 30 L pilot production run and begin developing an ISO9001 quality
control management protocol. (2) We will validate an assay for quantifying residual ELP-ZD. (3) We will
perform side-by-side purification of the NISTmAb at 30 L scale to compare IsoTag™ to leading PrA resins,
MAbSelect SuRe and Amsphere A3. Last, we will use BioSolve and Matlab software to develop a model for an
interface that takes a customerandapos;s inputs and calculates a personalized cost savings by switching to IsoTag™.
The outcome of this project will be compelling data that encourages customer conversion. Isolereandapos;s vision is
that IsoTag™ will be a plug-and-play downstream process that allows the industry to achieve fully integrated,
continuous manufacturing where improved productivity and lower cost can make mAbs globally accessible.PROJECT NARRATIVE
Monoclonal antibodies (mAb) are an important and fast growing drug class, but the first phase in
their purification process is a capture step via Protein A chromatography, which requires
expensive resin and equipment making it difficult and time consuming to execute at commercial
scale. Our IsoTag™ technology will provide an innovative, non-chromatographic alternative that
combines affinity/phase separation with microfiltration. IsoTag™ will create a paradigm shift in
the bioprocessing industry with its lower cost and continuous process that offers faster mass
transfer, milder elution conditions, and enhanced productivity. | Q145205 | 0.015514 | Resin | 22 |
000c24e7d3b5ae3c56c9c87ad2cca4330c1f05ca | Abstract
The objective of this NIH Phase II SBIR proposal is to demonstrate the commercial feasibility of IsoTag™, a
novel cost-effective method to purify monoclonal antibodies (mAbs) that eliminates the need for Protein A (PrA)
chromatography. This objective will be achieved by using a recombinant fusion comprised of a stimulus
responsive elastin-like polypeptide (ELP) that can undergo a reversible soluble to insoluble phase transition,
and the Z-domain (ZD) derived from PrA that binds the constant region of mAbs with high affinity and
specificity. This proposal is motivated by the fact that the first and critical step of mAb purification —PrA
affinity chromatography— has not kept pace with improvements in the recombinant expression level of mAbs,
creating a bottleneck in their production. IsoTag™, which combines affinity capture of mAbs and their isolation
by triggered phase separation with microfiltration, addresses this bottleneck. Upon addition of the ELP-ZD
fusion to clarified cell culture harvest, the ELP-ZD binds the mAb. Upon triggering the phase transition of the
mAb/ELP-ZD with a small amount of kosmotropic salt, the mAb/ELP-ZD complex undergoes liquid-liquid phase
separation into micron-sized droplets, allowing it to be separated from all soluble contaminants by continuous
tangential flow filtration, Next, the pH is lowered to ~4.0, which causes the ZD to lose its affinity for the mAb.
The pure, eluted mAb is in the soluble phase and the ELP-ZD can be regenerated from the insoluble phase. In
the NIH funded Phase I of this project, we have fully optimized the ELP-ZD and the process parameters for
IsoTag™ purification. We have shown that at the bench scale, IsoTag™ can be used to successfully isolate
mAb from mammalian cell culture with yields and contaminant removal that outperform commercially available
alternatives (GE Predictor Plate and Thermo Fisher Nab Spin Column). Having established technical feasibility
and developed a research use only, bench scale product, we plan to validate IsoTag™andapos;s commercial feasibility
for large-scale mAb purification in this Phase II proposal. Our Specific Aims to achieve this objective are: (1)
We will optimize microbial production of the ELP-ZD fusion using fermentation and develop a scalable
purification process. We will then perform a 30 L pilot production run and begin developing an ISO9001 quality
control management protocol. (2) We will validate an assay for quantifying residual ELP-ZD. (3) We will
perform side-by-side purification of the NISTmAb at 30 L scale to compare IsoTag™ to leading PrA resins,
MAbSelect SuRe and Amsphere A3. Last, we will use BioSolve and Matlab software to develop a model for an
interface that takes a customerandapos;s inputs and calculates a personalized cost savings by switching to IsoTag™.
The outcome of this project will be compelling data that encourages customer conversion. Isolereandapos;s vision is
that IsoTag™ will be a plug-and-play downstream process that allows the industry to achieve fully integrated,
continuous manufacturing where improved productivity and lower cost can make mAbs globally accessible.PROJECT NARRATIVE
Monoclonal antibodies (mAb) are an important and fast growing drug class, but the first phase in
their purification process is a capture step via Protein A chromatography, which requires
expensive resin and equipment making it difficult and time consuming to execute at commercial
scale. Our IsoTag™ technology will provide an innovative, non-chromatographic alternative that
combines affinity/phase separation with microfiltration. IsoTag™ will create a paradigm shift in
the bioprocessing industry with its lower cost and continuous process that offers faster mass
transfer, milder elution conditions, and enhanced productivity. | Q3130283 | 0.015215 | List of purification methods in chemistry | 23 |
000c24e7d3b5ae3c56c9c87ad2cca4330c1f05ca | Abstract
The objective of this NIH Phase II SBIR proposal is to demonstrate the commercial feasibility of IsoTag™, a
novel cost-effective method to purify monoclonal antibodies (mAbs) that eliminates the need for Protein A (PrA)
chromatography. This objective will be achieved by using a recombinant fusion comprised of a stimulus
responsive elastin-like polypeptide (ELP) that can undergo a reversible soluble to insoluble phase transition,
and the Z-domain (ZD) derived from PrA that binds the constant region of mAbs with high affinity and
specificity. This proposal is motivated by the fact that the first and critical step of mAb purification —PrA
affinity chromatography— has not kept pace with improvements in the recombinant expression level of mAbs,
creating a bottleneck in their production. IsoTag™, which combines affinity capture of mAbs and their isolation
by triggered phase separation with microfiltration, addresses this bottleneck. Upon addition of the ELP-ZD
fusion to clarified cell culture harvest, the ELP-ZD binds the mAb. Upon triggering the phase transition of the
mAb/ELP-ZD with a small amount of kosmotropic salt, the mAb/ELP-ZD complex undergoes liquid-liquid phase
separation into micron-sized droplets, allowing it to be separated from all soluble contaminants by continuous
tangential flow filtration, Next, the pH is lowered to ~4.0, which causes the ZD to lose its affinity for the mAb.
The pure, eluted mAb is in the soluble phase and the ELP-ZD can be regenerated from the insoluble phase. In
the NIH funded Phase I of this project, we have fully optimized the ELP-ZD and the process parameters for
IsoTag™ purification. We have shown that at the bench scale, IsoTag™ can be used to successfully isolate
mAb from mammalian cell culture with yields and contaminant removal that outperform commercially available
alternatives (GE Predictor Plate and Thermo Fisher Nab Spin Column). Having established technical feasibility
and developed a research use only, bench scale product, we plan to validate IsoTag™andapos;s commercial feasibility
for large-scale mAb purification in this Phase II proposal. Our Specific Aims to achieve this objective are: (1)
We will optimize microbial production of the ELP-ZD fusion using fermentation and develop a scalable
purification process. We will then perform a 30 L pilot production run and begin developing an ISO9001 quality
control management protocol. (2) We will validate an assay for quantifying residual ELP-ZD. (3) We will
perform side-by-side purification of the NISTmAb at 30 L scale to compare IsoTag™ to leading PrA resins,
MAbSelect SuRe and Amsphere A3. Last, we will use BioSolve and Matlab software to develop a model for an
interface that takes a customerandapos;s inputs and calculates a personalized cost savings by switching to IsoTag™.
The outcome of this project will be compelling data that encourages customer conversion. Isolereandapos;s vision is
that IsoTag™ will be a plug-and-play downstream process that allows the industry to achieve fully integrated,
continuous manufacturing where improved productivity and lower cost can make mAbs globally accessible.PROJECT NARRATIVE
Monoclonal antibodies (mAb) are an important and fast growing drug class, but the first phase in
their purification process is a capture step via Protein A chromatography, which requires
expensive resin and equipment making it difficult and time consuming to execute at commercial
scale. Our IsoTag™ technology will provide an innovative, non-chromatographic alternative that
combines affinity/phase separation with microfiltration. IsoTag™ will create a paradigm shift in
the bioprocessing industry with its lower cost and continuous process that offers faster mass
transfer, milder elution conditions, and enhanced productivity. | Q5113746 | 0.015026 | Chromatography in blood processing | 24 |
000c24e7d3b5ae3c56c9c87ad2cca4330c1f05ca | Abstract
The objective of this NIH Phase II SBIR proposal is to demonstrate the commercial feasibility of IsoTag™, a
novel cost-effective method to purify monoclonal antibodies (mAbs) that eliminates the need for Protein A (PrA)
chromatography. This objective will be achieved by using a recombinant fusion comprised of a stimulus
responsive elastin-like polypeptide (ELP) that can undergo a reversible soluble to insoluble phase transition,
and the Z-domain (ZD) derived from PrA that binds the constant region of mAbs with high affinity and
specificity. This proposal is motivated by the fact that the first and critical step of mAb purification —PrA
affinity chromatography— has not kept pace with improvements in the recombinant expression level of mAbs,
creating a bottleneck in their production. IsoTag™, which combines affinity capture of mAbs and their isolation
by triggered phase separation with microfiltration, addresses this bottleneck. Upon addition of the ELP-ZD
fusion to clarified cell culture harvest, the ELP-ZD binds the mAb. Upon triggering the phase transition of the
mAb/ELP-ZD with a small amount of kosmotropic salt, the mAb/ELP-ZD complex undergoes liquid-liquid phase
separation into micron-sized droplets, allowing it to be separated from all soluble contaminants by continuous
tangential flow filtration, Next, the pH is lowered to ~4.0, which causes the ZD to lose its affinity for the mAb.
The pure, eluted mAb is in the soluble phase and the ELP-ZD can be regenerated from the insoluble phase. In
the NIH funded Phase I of this project, we have fully optimized the ELP-ZD and the process parameters for
IsoTag™ purification. We have shown that at the bench scale, IsoTag™ can be used to successfully isolate
mAb from mammalian cell culture with yields and contaminant removal that outperform commercially available
alternatives (GE Predictor Plate and Thermo Fisher Nab Spin Column). Having established technical feasibility
and developed a research use only, bench scale product, we plan to validate IsoTag™andapos;s commercial feasibility
for large-scale mAb purification in this Phase II proposal. Our Specific Aims to achieve this objective are: (1)
We will optimize microbial production of the ELP-ZD fusion using fermentation and develop a scalable
purification process. We will then perform a 30 L pilot production run and begin developing an ISO9001 quality
control management protocol. (2) We will validate an assay for quantifying residual ELP-ZD. (3) We will
perform side-by-side purification of the NISTmAb at 30 L scale to compare IsoTag™ to leading PrA resins,
MAbSelect SuRe and Amsphere A3. Last, we will use BioSolve and Matlab software to develop a model for an
interface that takes a customerandapos;s inputs and calculates a personalized cost savings by switching to IsoTag™.
The outcome of this project will be compelling data that encourages customer conversion. Isolereandapos;s vision is
that IsoTag™ will be a plug-and-play downstream process that allows the industry to achieve fully integrated,
continuous manufacturing where improved productivity and lower cost can make mAbs globally accessible.PROJECT NARRATIVE
Monoclonal antibodies (mAb) are an important and fast growing drug class, but the first phase in
their purification process is a capture step via Protein A chromatography, which requires
expensive resin and equipment making it difficult and time consuming to execute at commercial
scale. Our IsoTag™ technology will provide an innovative, non-chromatographic alternative that
combines affinity/phase separation with microfiltration. IsoTag™ will create a paradigm shift in
the bioprocessing industry with its lower cost and continuous process that offers faster mass
transfer, milder elution conditions, and enhanced productivity. | Q1339474 | 0.014785 | Maternal death | 25 |
000c24e7d3b5ae3c56c9c87ad2cca4330c1f05ca | Abstract
The objective of this NIH Phase II SBIR proposal is to demonstrate the commercial feasibility of IsoTag™, a
novel cost-effective method to purify monoclonal antibodies (mAbs) that eliminates the need for Protein A (PrA)
chromatography. This objective will be achieved by using a recombinant fusion comprised of a stimulus
responsive elastin-like polypeptide (ELP) that can undergo a reversible soluble to insoluble phase transition,
and the Z-domain (ZD) derived from PrA that binds the constant region of mAbs with high affinity and
specificity. This proposal is motivated by the fact that the first and critical step of mAb purification —PrA
affinity chromatography— has not kept pace with improvements in the recombinant expression level of mAbs,
creating a bottleneck in their production. IsoTag™, which combines affinity capture of mAbs and their isolation
by triggered phase separation with microfiltration, addresses this bottleneck. Upon addition of the ELP-ZD
fusion to clarified cell culture harvest, the ELP-ZD binds the mAb. Upon triggering the phase transition of the
mAb/ELP-ZD with a small amount of kosmotropic salt, the mAb/ELP-ZD complex undergoes liquid-liquid phase
separation into micron-sized droplets, allowing it to be separated from all soluble contaminants by continuous
tangential flow filtration, Next, the pH is lowered to ~4.0, which causes the ZD to lose its affinity for the mAb.
The pure, eluted mAb is in the soluble phase and the ELP-ZD can be regenerated from the insoluble phase. In
the NIH funded Phase I of this project, we have fully optimized the ELP-ZD and the process parameters for
IsoTag™ purification. We have shown that at the bench scale, IsoTag™ can be used to successfully isolate
mAb from mammalian cell culture with yields and contaminant removal that outperform commercially available
alternatives (GE Predictor Plate and Thermo Fisher Nab Spin Column). Having established technical feasibility
and developed a research use only, bench scale product, we plan to validate IsoTag™andapos;s commercial feasibility
for large-scale mAb purification in this Phase II proposal. Our Specific Aims to achieve this objective are: (1)
We will optimize microbial production of the ELP-ZD fusion using fermentation and develop a scalable
purification process. We will then perform a 30 L pilot production run and begin developing an ISO9001 quality
control management protocol. (2) We will validate an assay for quantifying residual ELP-ZD. (3) We will
perform side-by-side purification of the NISTmAb at 30 L scale to compare IsoTag™ to leading PrA resins,
MAbSelect SuRe and Amsphere A3. Last, we will use BioSolve and Matlab software to develop a model for an
interface that takes a customerandapos;s inputs and calculates a personalized cost savings by switching to IsoTag™.
The outcome of this project will be compelling data that encourages customer conversion. Isolereandapos;s vision is
that IsoTag™ will be a plug-and-play downstream process that allows the industry to achieve fully integrated,
continuous manufacturing where improved productivity and lower cost can make mAbs globally accessible.PROJECT NARRATIVE
Monoclonal antibodies (mAb) are an important and fast growing drug class, but the first phase in
their purification process is a capture step via Protein A chromatography, which requires
expensive resin and equipment making it difficult and time consuming to execute at commercial
scale. Our IsoTag™ technology will provide an innovative, non-chromatographic alternative that
combines affinity/phase separation with microfiltration. IsoTag™ will create a paradigm shift in
the bioprocessing industry with its lower cost and continuous process that offers faster mass
transfer, milder elution conditions, and enhanced productivity. | Q739897 | 0.014353 | Assay | 26 |
000c24e7d3b5ae3c56c9c87ad2cca4330c1f05ca | Abstract
The objective of this NIH Phase II SBIR proposal is to demonstrate the commercial feasibility of IsoTag™, a
novel cost-effective method to purify monoclonal antibodies (mAbs) that eliminates the need for Protein A (PrA)
chromatography. This objective will be achieved by using a recombinant fusion comprised of a stimulus
responsive elastin-like polypeptide (ELP) that can undergo a reversible soluble to insoluble phase transition,
and the Z-domain (ZD) derived from PrA that binds the constant region of mAbs with high affinity and
specificity. This proposal is motivated by the fact that the first and critical step of mAb purification —PrA
affinity chromatography— has not kept pace with improvements in the recombinant expression level of mAbs,
creating a bottleneck in their production. IsoTag™, which combines affinity capture of mAbs and their isolation
by triggered phase separation with microfiltration, addresses this bottleneck. Upon addition of the ELP-ZD
fusion to clarified cell culture harvest, the ELP-ZD binds the mAb. Upon triggering the phase transition of the
mAb/ELP-ZD with a small amount of kosmotropic salt, the mAb/ELP-ZD complex undergoes liquid-liquid phase
separation into micron-sized droplets, allowing it to be separated from all soluble contaminants by continuous
tangential flow filtration, Next, the pH is lowered to ~4.0, which causes the ZD to lose its affinity for the mAb.
The pure, eluted mAb is in the soluble phase and the ELP-ZD can be regenerated from the insoluble phase. In
the NIH funded Phase I of this project, we have fully optimized the ELP-ZD and the process parameters for
IsoTag™ purification. We have shown that at the bench scale, IsoTag™ can be used to successfully isolate
mAb from mammalian cell culture with yields and contaminant removal that outperform commercially available
alternatives (GE Predictor Plate and Thermo Fisher Nab Spin Column). Having established technical feasibility
and developed a research use only, bench scale product, we plan to validate IsoTag™andapos;s commercial feasibility
for large-scale mAb purification in this Phase II proposal. Our Specific Aims to achieve this objective are: (1)
We will optimize microbial production of the ELP-ZD fusion using fermentation and develop a scalable
purification process. We will then perform a 30 L pilot production run and begin developing an ISO9001 quality
control management protocol. (2) We will validate an assay for quantifying residual ELP-ZD. (3) We will
perform side-by-side purification of the NISTmAb at 30 L scale to compare IsoTag™ to leading PrA resins,
MAbSelect SuRe and Amsphere A3. Last, we will use BioSolve and Matlab software to develop a model for an
interface that takes a customerandapos;s inputs and calculates a personalized cost savings by switching to IsoTag™.
The outcome of this project will be compelling data that encourages customer conversion. Isolereandapos;s vision is
that IsoTag™ will be a plug-and-play downstream process that allows the industry to achieve fully integrated,
continuous manufacturing where improved productivity and lower cost can make mAbs globally accessible.PROJECT NARRATIVE
Monoclonal antibodies (mAb) are an important and fast growing drug class, but the first phase in
their purification process is a capture step via Protein A chromatography, which requires
expensive resin and equipment making it difficult and time consuming to execute at commercial
scale. Our IsoTag™ technology will provide an innovative, non-chromatographic alternative that
combines affinity/phase separation with microfiltration. IsoTag™ will create a paradigm shift in
the bioprocessing industry with its lower cost and continuous process that offers faster mass
transfer, milder elution conditions, and enhanced productivity. | Q54173 | 0.014335 | General Electric | 27 |
000c24e7d3b5ae3c56c9c87ad2cca4330c1f05ca | Abstract
The objective of this NIH Phase II SBIR proposal is to demonstrate the commercial feasibility of IsoTag™, a
novel cost-effective method to purify monoclonal antibodies (mAbs) that eliminates the need for Protein A (PrA)
chromatography. This objective will be achieved by using a recombinant fusion comprised of a stimulus
responsive elastin-like polypeptide (ELP) that can undergo a reversible soluble to insoluble phase transition,
and the Z-domain (ZD) derived from PrA that binds the constant region of mAbs with high affinity and
specificity. This proposal is motivated by the fact that the first and critical step of mAb purification —PrA
affinity chromatography— has not kept pace with improvements in the recombinant expression level of mAbs,
creating a bottleneck in their production. IsoTag™, which combines affinity capture of mAbs and their isolation
by triggered phase separation with microfiltration, addresses this bottleneck. Upon addition of the ELP-ZD
fusion to clarified cell culture harvest, the ELP-ZD binds the mAb. Upon triggering the phase transition of the
mAb/ELP-ZD with a small amount of kosmotropic salt, the mAb/ELP-ZD complex undergoes liquid-liquid phase
separation into micron-sized droplets, allowing it to be separated from all soluble contaminants by continuous
tangential flow filtration, Next, the pH is lowered to ~4.0, which causes the ZD to lose its affinity for the mAb.
The pure, eluted mAb is in the soluble phase and the ELP-ZD can be regenerated from the insoluble phase. In
the NIH funded Phase I of this project, we have fully optimized the ELP-ZD and the process parameters for
IsoTag™ purification. We have shown that at the bench scale, IsoTag™ can be used to successfully isolate
mAb from mammalian cell culture with yields and contaminant removal that outperform commercially available
alternatives (GE Predictor Plate and Thermo Fisher Nab Spin Column). Having established technical feasibility
and developed a research use only, bench scale product, we plan to validate IsoTag™andapos;s commercial feasibility
for large-scale mAb purification in this Phase II proposal. Our Specific Aims to achieve this objective are: (1)
We will optimize microbial production of the ELP-ZD fusion using fermentation and develop a scalable
purification process. We will then perform a 30 L pilot production run and begin developing an ISO9001 quality
control management protocol. (2) We will validate an assay for quantifying residual ELP-ZD. (3) We will
perform side-by-side purification of the NISTmAb at 30 L scale to compare IsoTag™ to leading PrA resins,
MAbSelect SuRe and Amsphere A3. Last, we will use BioSolve and Matlab software to develop a model for an
interface that takes a customerandapos;s inputs and calculates a personalized cost savings by switching to IsoTag™.
The outcome of this project will be compelling data that encourages customer conversion. Isolereandapos;s vision is
that IsoTag™ will be a plug-and-play downstream process that allows the industry to achieve fully integrated,
continuous manufacturing where improved productivity and lower cost can make mAbs globally accessible.PROJECT NARRATIVE
Monoclonal antibodies (mAb) are an important and fast growing drug class, but the first phase in
their purification process is a capture step via Protein A chromatography, which requires
expensive resin and equipment making it difficult and time consuming to execute at commercial
scale. Our IsoTag™ technology will provide an innovative, non-chromatographic alternative that
combines affinity/phase separation with microfiltration. IsoTag™ will create a paradigm shift in
the bioprocessing industry with its lower cost and continuous process that offers faster mass
transfer, milder elution conditions, and enhanced productivity. | Q2976049 | 0.01426 | Drug class | 28 |
000c24e7d3b5ae3c56c9c87ad2cca4330c1f05ca | Abstract
The objective of this NIH Phase II SBIR proposal is to demonstrate the commercial feasibility of IsoTag™, a
novel cost-effective method to purify monoclonal antibodies (mAbs) that eliminates the need for Protein A (PrA)
chromatography. This objective will be achieved by using a recombinant fusion comprised of a stimulus
responsive elastin-like polypeptide (ELP) that can undergo a reversible soluble to insoluble phase transition,
and the Z-domain (ZD) derived from PrA that binds the constant region of mAbs with high affinity and
specificity. This proposal is motivated by the fact that the first and critical step of mAb purification —PrA
affinity chromatography— has not kept pace with improvements in the recombinant expression level of mAbs,
creating a bottleneck in their production. IsoTag™, which combines affinity capture of mAbs and their isolation
by triggered phase separation with microfiltration, addresses this bottleneck. Upon addition of the ELP-ZD
fusion to clarified cell culture harvest, the ELP-ZD binds the mAb. Upon triggering the phase transition of the
mAb/ELP-ZD with a small amount of kosmotropic salt, the mAb/ELP-ZD complex undergoes liquid-liquid phase
separation into micron-sized droplets, allowing it to be separated from all soluble contaminants by continuous
tangential flow filtration, Next, the pH is lowered to ~4.0, which causes the ZD to lose its affinity for the mAb.
The pure, eluted mAb is in the soluble phase and the ELP-ZD can be regenerated from the insoluble phase. In
the NIH funded Phase I of this project, we have fully optimized the ELP-ZD and the process parameters for
IsoTag™ purification. We have shown that at the bench scale, IsoTag™ can be used to successfully isolate
mAb from mammalian cell culture with yields and contaminant removal that outperform commercially available
alternatives (GE Predictor Plate and Thermo Fisher Nab Spin Column). Having established technical feasibility
and developed a research use only, bench scale product, we plan to validate IsoTag™andapos;s commercial feasibility
for large-scale mAb purification in this Phase II proposal. Our Specific Aims to achieve this objective are: (1)
We will optimize microbial production of the ELP-ZD fusion using fermentation and develop a scalable
purification process. We will then perform a 30 L pilot production run and begin developing an ISO9001 quality
control management protocol. (2) We will validate an assay for quantifying residual ELP-ZD. (3) We will
perform side-by-side purification of the NISTmAb at 30 L scale to compare IsoTag™ to leading PrA resins,
MAbSelect SuRe and Amsphere A3. Last, we will use BioSolve and Matlab software to develop a model for an
interface that takes a customerandapos;s inputs and calculates a personalized cost savings by switching to IsoTag™.
The outcome of this project will be compelling data that encourages customer conversion. Isolereandapos;s vision is
that IsoTag™ will be a plug-and-play downstream process that allows the industry to achieve fully integrated,
continuous manufacturing where improved productivity and lower cost can make mAbs globally accessible.PROJECT NARRATIVE
Monoclonal antibodies (mAb) are an important and fast growing drug class, but the first phase in
their purification process is a capture step via Protein A chromatography, which requires
expensive resin and equipment making it difficult and time consuming to execute at commercial
scale. Our IsoTag™ technology will provide an innovative, non-chromatographic alternative that
combines affinity/phase separation with microfiltration. IsoTag™ will create a paradigm shift in
the bioprocessing industry with its lower cost and continuous process that offers faster mass
transfer, milder elution conditions, and enhanced productivity. | Q219285 | 0.014062 | Fusion | 29 |
000c24e7d3b5ae3c56c9c87ad2cca4330c1f05ca | Abstract
The objective of this NIH Phase II SBIR proposal is to demonstrate the commercial feasibility of IsoTag™, a
novel cost-effective method to purify monoclonal antibodies (mAbs) that eliminates the need for Protein A (PrA)
chromatography. This objective will be achieved by using a recombinant fusion comprised of a stimulus
responsive elastin-like polypeptide (ELP) that can undergo a reversible soluble to insoluble phase transition,
and the Z-domain (ZD) derived from PrA that binds the constant region of mAbs with high affinity and
specificity. This proposal is motivated by the fact that the first and critical step of mAb purification —PrA
affinity chromatography— has not kept pace with improvements in the recombinant expression level of mAbs,
creating a bottleneck in their production. IsoTag™, which combines affinity capture of mAbs and their isolation
by triggered phase separation with microfiltration, addresses this bottleneck. Upon addition of the ELP-ZD
fusion to clarified cell culture harvest, the ELP-ZD binds the mAb. Upon triggering the phase transition of the
mAb/ELP-ZD with a small amount of kosmotropic salt, the mAb/ELP-ZD complex undergoes liquid-liquid phase
separation into micron-sized droplets, allowing it to be separated from all soluble contaminants by continuous
tangential flow filtration, Next, the pH is lowered to ~4.0, which causes the ZD to lose its affinity for the mAb.
The pure, eluted mAb is in the soluble phase and the ELP-ZD can be regenerated from the insoluble phase. In
the NIH funded Phase I of this project, we have fully optimized the ELP-ZD and the process parameters for
IsoTag™ purification. We have shown that at the bench scale, IsoTag™ can be used to successfully isolate
mAb from mammalian cell culture with yields and contaminant removal that outperform commercially available
alternatives (GE Predictor Plate and Thermo Fisher Nab Spin Column). Having established technical feasibility
and developed a research use only, bench scale product, we plan to validate IsoTag™andapos;s commercial feasibility
for large-scale mAb purification in this Phase II proposal. Our Specific Aims to achieve this objective are: (1)
We will optimize microbial production of the ELP-ZD fusion using fermentation and develop a scalable
purification process. We will then perform a 30 L pilot production run and begin developing an ISO9001 quality
control management protocol. (2) We will validate an assay for quantifying residual ELP-ZD. (3) We will
perform side-by-side purification of the NISTmAb at 30 L scale to compare IsoTag™ to leading PrA resins,
MAbSelect SuRe and Amsphere A3. Last, we will use BioSolve and Matlab software to develop a model for an
interface that takes a customerandapos;s inputs and calculates a personalized cost savings by switching to IsoTag™.
The outcome of this project will be compelling data that encourages customer conversion. Isolereandapos;s vision is
that IsoTag™ will be a plug-and-play downstream process that allows the industry to achieve fully integrated,
continuous manufacturing where improved productivity and lower cost can make mAbs globally accessible.PROJECT NARRATIVE
Monoclonal antibodies (mAb) are an important and fast growing drug class, but the first phase in
their purification process is a capture step via Protein A chromatography, which requires
expensive resin and equipment making it difficult and time consuming to execute at commercial
scale. Our IsoTag™ technology will provide an innovative, non-chromatographic alternative that
combines affinity/phase separation with microfiltration. IsoTag™ will create a paradigm shift in
the bioprocessing industry with its lower cost and continuous process that offers faster mass
transfer, milder elution conditions, and enhanced productivity. | Q17084289 | 0.014056 | Synthetic antibody | 30 |
000e80047232b2c222bdd84df6731e882a4dd6bd | EXTENDED SPACE MISSIONS REQUIRE EXTENSIVE RECYCLING OF WATERTO PERMIT FREQUENT WASHING AND BATHING OF THE CREW. REVERSEOSMOSIS (RO), OFTEN CALLED HYPERFILTRATION, PROMISES TO BE A UNIQUELY SUITED TECHNOLOGY FOR WATER RECYCLING IN SPACECRAFT. HOWEVER, CURRENT MEMBRANE MODULE DESIGNS HAVE TWO MAJOR SHORTCOMINGS FOR THIS APPLICATION: (1) THEY ARE EASILY FOULED BY BACTERIA AND SUSPENDED MATTER FOUND IN WASHWATER, AND (2) THEY ARE RELATIVELY HEAVY. THIS EFFORT INVESTIGATES A NEW TYPE OF RO MEMBRAME MODULE BASED ON A TUBE-SIDE-FEED HOLLOW-FIBER MEMBRANE CONFIGURATION THAT OVERCOMES BOTH SHORTCOMINGS. POSITIVE FEED FLOW WITHIN THE HOLLOW-FIBER LUMENS IS EXPECTED TO MINIMIZE FOULING. BECAUSE THE FIBERS THEMSELVES SERVE AS PRESSURE VESSELS, NO HEAVY EXTERNAL PRESSURE VESSEL IS REQUIRED. IT IS ESTIMATED THAT A MODULE OF THIS DESIGN WOULD BE ABOUT 1/16 THE WEIGHT OF A CONVENTIONAL MODULE AND WOULD REQUIRE ABOUT 1/2 THE SPACE. THE PHASE I PROGRAM DEMONSTRATES THE FOULINGRESISTANCE OF THIS MODULE CONFIGURATION DURING PROLONGED TREATMENT OF ACTUAL WASHWATER USING WATER-DESALTING MODULES ALREADY UNDER DEVELOPMENT. A PROTOTYPE LIGHT-WEIGHT , HIGH PRODUCTIVITY MODULE SPECIFICALLY DESIGNED FOR WASHWATER RECYCLING IS CONSTRUCTED AND TESTED. BASED ON THE TECHNICALRESULTS, A DESIGN ANALYSIS OF RO FOR SPACE VEHICLE WASHWATERRECYCLING IS CONDUCTED. | Q740460 | 0.075494 | Pressure vessel | 1 |
000e80047232b2c222bdd84df6731e882a4dd6bd | EXTENDED SPACE MISSIONS REQUIRE EXTENSIVE RECYCLING OF WATERTO PERMIT FREQUENT WASHING AND BATHING OF THE CREW. REVERSEOSMOSIS (RO), OFTEN CALLED HYPERFILTRATION, PROMISES TO BE A UNIQUELY SUITED TECHNOLOGY FOR WATER RECYCLING IN SPACECRAFT. HOWEVER, CURRENT MEMBRANE MODULE DESIGNS HAVE TWO MAJOR SHORTCOMINGS FOR THIS APPLICATION: (1) THEY ARE EASILY FOULED BY BACTERIA AND SUSPENDED MATTER FOUND IN WASHWATER, AND (2) THEY ARE RELATIVELY HEAVY. THIS EFFORT INVESTIGATES A NEW TYPE OF RO MEMBRAME MODULE BASED ON A TUBE-SIDE-FEED HOLLOW-FIBER MEMBRANE CONFIGURATION THAT OVERCOMES BOTH SHORTCOMINGS. POSITIVE FEED FLOW WITHIN THE HOLLOW-FIBER LUMENS IS EXPECTED TO MINIMIZE FOULING. BECAUSE THE FIBERS THEMSELVES SERVE AS PRESSURE VESSELS, NO HEAVY EXTERNAL PRESSURE VESSEL IS REQUIRED. IT IS ESTIMATED THAT A MODULE OF THIS DESIGN WOULD BE ABOUT 1/16 THE WEIGHT OF A CONVENTIONAL MODULE AND WOULD REQUIRE ABOUT 1/2 THE SPACE. THE PHASE I PROGRAM DEMONSTRATES THE FOULINGRESISTANCE OF THIS MODULE CONFIGURATION DURING PROLONGED TREATMENT OF ACTUAL WASHWATER USING WATER-DESALTING MODULES ALREADY UNDER DEVELOPMENT. A PROTOTYPE LIGHT-WEIGHT , HIGH PRODUCTIVITY MODULE SPECIFICALLY DESIGNED FOR WASHWATER RECYCLING IS CONSTRUCTED AND TESTED. BASED ON THE TECHNICALRESULTS, A DESIGN ANALYSIS OF RO FOR SPACE VEHICLE WASHWATERRECYCLING IS CONDUCTED. | Q6155882 | 0.041639 | Space missions | 2 |
000e80047232b2c222bdd84df6731e882a4dd6bd | EXTENDED SPACE MISSIONS REQUIRE EXTENSIVE RECYCLING OF WATERTO PERMIT FREQUENT WASHING AND BATHING OF THE CREW. REVERSEOSMOSIS (RO), OFTEN CALLED HYPERFILTRATION, PROMISES TO BE A UNIQUELY SUITED TECHNOLOGY FOR WATER RECYCLING IN SPACECRAFT. HOWEVER, CURRENT MEMBRANE MODULE DESIGNS HAVE TWO MAJOR SHORTCOMINGS FOR THIS APPLICATION: (1) THEY ARE EASILY FOULED BY BACTERIA AND SUSPENDED MATTER FOUND IN WASHWATER, AND (2) THEY ARE RELATIVELY HEAVY. THIS EFFORT INVESTIGATES A NEW TYPE OF RO MEMBRAME MODULE BASED ON A TUBE-SIDE-FEED HOLLOW-FIBER MEMBRANE CONFIGURATION THAT OVERCOMES BOTH SHORTCOMINGS. POSITIVE FEED FLOW WITHIN THE HOLLOW-FIBER LUMENS IS EXPECTED TO MINIMIZE FOULING. BECAUSE THE FIBERS THEMSELVES SERVE AS PRESSURE VESSELS, NO HEAVY EXTERNAL PRESSURE VESSEL IS REQUIRED. IT IS ESTIMATED THAT A MODULE OF THIS DESIGN WOULD BE ABOUT 1/16 THE WEIGHT OF A CONVENTIONAL MODULE AND WOULD REQUIRE ABOUT 1/2 THE SPACE. THE PHASE I PROGRAM DEMONSTRATES THE FOULINGRESISTANCE OF THIS MODULE CONFIGURATION DURING PROLONGED TREATMENT OF ACTUAL WASHWATER USING WATER-DESALTING MODULES ALREADY UNDER DEVELOPMENT. A PROTOTYPE LIGHT-WEIGHT , HIGH PRODUCTIVITY MODULE SPECIFICALLY DESIGNED FOR WASHWATER RECYCLING IS CONSTRUCTED AND TESTED. BASED ON THE TECHNICALRESULTS, A DESIGN ANALYSIS OF RO FOR SPACE VEHICLE WASHWATERRECYCLING IS CONDUCTED. | Q4043142 | 0.039283 | Module | 3 |
000e80047232b2c222bdd84df6731e882a4dd6bd | EXTENDED SPACE MISSIONS REQUIRE EXTENSIVE RECYCLING OF WATERTO PERMIT FREQUENT WASHING AND BATHING OF THE CREW. REVERSEOSMOSIS (RO), OFTEN CALLED HYPERFILTRATION, PROMISES TO BE A UNIQUELY SUITED TECHNOLOGY FOR WATER RECYCLING IN SPACECRAFT. HOWEVER, CURRENT MEMBRANE MODULE DESIGNS HAVE TWO MAJOR SHORTCOMINGS FOR THIS APPLICATION: (1) THEY ARE EASILY FOULED BY BACTERIA AND SUSPENDED MATTER FOUND IN WASHWATER, AND (2) THEY ARE RELATIVELY HEAVY. THIS EFFORT INVESTIGATES A NEW TYPE OF RO MEMBRAME MODULE BASED ON A TUBE-SIDE-FEED HOLLOW-FIBER MEMBRANE CONFIGURATION THAT OVERCOMES BOTH SHORTCOMINGS. POSITIVE FEED FLOW WITHIN THE HOLLOW-FIBER LUMENS IS EXPECTED TO MINIMIZE FOULING. BECAUSE THE FIBERS THEMSELVES SERVE AS PRESSURE VESSELS, NO HEAVY EXTERNAL PRESSURE VESSEL IS REQUIRED. IT IS ESTIMATED THAT A MODULE OF THIS DESIGN WOULD BE ABOUT 1/16 THE WEIGHT OF A CONVENTIONAL MODULE AND WOULD REQUIRE ABOUT 1/2 THE SPACE. THE PHASE I PROGRAM DEMONSTRATES THE FOULINGRESISTANCE OF THIS MODULE CONFIGURATION DURING PROLONGED TREATMENT OF ACTUAL WASHWATER USING WATER-DESALTING MODULES ALREADY UNDER DEVELOPMENT. A PROTOTYPE LIGHT-WEIGHT , HIGH PRODUCTIVITY MODULE SPECIFICALLY DESIGNED FOR WASHWATER RECYCLING IS CONSTRUCTED AND TESTED. BASED ON THE TECHNICALRESULTS, A DESIGN ANALYSIS OF RO FOR SPACE VEHICLE WASHWATERRECYCLING IS CONDUCTED. | Q132580 | 0.028842 | Recycling | 4 |
000e80047232b2c222bdd84df6731e882a4dd6bd | EXTENDED SPACE MISSIONS REQUIRE EXTENSIVE RECYCLING OF WATERTO PERMIT FREQUENT WASHING AND BATHING OF THE CREW. REVERSEOSMOSIS (RO), OFTEN CALLED HYPERFILTRATION, PROMISES TO BE A UNIQUELY SUITED TECHNOLOGY FOR WATER RECYCLING IN SPACECRAFT. HOWEVER, CURRENT MEMBRANE MODULE DESIGNS HAVE TWO MAJOR SHORTCOMINGS FOR THIS APPLICATION: (1) THEY ARE EASILY FOULED BY BACTERIA AND SUSPENDED MATTER FOUND IN WASHWATER, AND (2) THEY ARE RELATIVELY HEAVY. THIS EFFORT INVESTIGATES A NEW TYPE OF RO MEMBRAME MODULE BASED ON A TUBE-SIDE-FEED HOLLOW-FIBER MEMBRANE CONFIGURATION THAT OVERCOMES BOTH SHORTCOMINGS. POSITIVE FEED FLOW WITHIN THE HOLLOW-FIBER LUMENS IS EXPECTED TO MINIMIZE FOULING. BECAUSE THE FIBERS THEMSELVES SERVE AS PRESSURE VESSELS, NO HEAVY EXTERNAL PRESSURE VESSEL IS REQUIRED. IT IS ESTIMATED THAT A MODULE OF THIS DESIGN WOULD BE ABOUT 1/16 THE WEIGHT OF A CONVENTIONAL MODULE AND WOULD REQUIRE ABOUT 1/2 THE SPACE. THE PHASE I PROGRAM DEMONSTRATES THE FOULINGRESISTANCE OF THIS MODULE CONFIGURATION DURING PROLONGED TREATMENT OF ACTUAL WASHWATER USING WATER-DESALTING MODULES ALREADY UNDER DEVELOPMENT. A PROTOTYPE LIGHT-WEIGHT , HIGH PRODUCTIVITY MODULE SPECIFICALLY DESIGNED FOR WASHWATER RECYCLING IS CONSTRUCTED AND TESTED. BASED ON THE TECHNICALRESULTS, A DESIGN ANALYSIS OF RO FOR SPACE VEHICLE WASHWATERRECYCLING IS CONDUCTED. | Q25325287 | 0.026049 | Hollow fiber membrane | 5 |
000e80047232b2c222bdd84df6731e882a4dd6bd | EXTENDED SPACE MISSIONS REQUIRE EXTENSIVE RECYCLING OF WATERTO PERMIT FREQUENT WASHING AND BATHING OF THE CREW. REVERSEOSMOSIS (RO), OFTEN CALLED HYPERFILTRATION, PROMISES TO BE A UNIQUELY SUITED TECHNOLOGY FOR WATER RECYCLING IN SPACECRAFT. HOWEVER, CURRENT MEMBRANE MODULE DESIGNS HAVE TWO MAJOR SHORTCOMINGS FOR THIS APPLICATION: (1) THEY ARE EASILY FOULED BY BACTERIA AND SUSPENDED MATTER FOUND IN WASHWATER, AND (2) THEY ARE RELATIVELY HEAVY. THIS EFFORT INVESTIGATES A NEW TYPE OF RO MEMBRAME MODULE BASED ON A TUBE-SIDE-FEED HOLLOW-FIBER MEMBRANE CONFIGURATION THAT OVERCOMES BOTH SHORTCOMINGS. POSITIVE FEED FLOW WITHIN THE HOLLOW-FIBER LUMENS IS EXPECTED TO MINIMIZE FOULING. BECAUSE THE FIBERS THEMSELVES SERVE AS PRESSURE VESSELS, NO HEAVY EXTERNAL PRESSURE VESSEL IS REQUIRED. IT IS ESTIMATED THAT A MODULE OF THIS DESIGN WOULD BE ABOUT 1/16 THE WEIGHT OF A CONVENTIONAL MODULE AND WOULD REQUIRE ABOUT 1/2 THE SPACE. THE PHASE I PROGRAM DEMONSTRATES THE FOULINGRESISTANCE OF THIS MODULE CONFIGURATION DURING PROLONGED TREATMENT OF ACTUAL WASHWATER USING WATER-DESALTING MODULES ALREADY UNDER DEVELOPMENT. A PROTOTYPE LIGHT-WEIGHT , HIGH PRODUCTIVITY MODULE SPECIFICALLY DESIGNED FOR WASHWATER RECYCLING IS CONSTRUCTED AND TESTED. BASED ON THE TECHNICALRESULTS, A DESIGN ANALYSIS OF RO FOR SPACE VEHICLE WASHWATERRECYCLING IS CONDUCTED. | Q110516951 | 0.025335 | International Habitation Module | 6 |
000e80047232b2c222bdd84df6731e882a4dd6bd | EXTENDED SPACE MISSIONS REQUIRE EXTENSIVE RECYCLING OF WATERTO PERMIT FREQUENT WASHING AND BATHING OF THE CREW. REVERSEOSMOSIS (RO), OFTEN CALLED HYPERFILTRATION, PROMISES TO BE A UNIQUELY SUITED TECHNOLOGY FOR WATER RECYCLING IN SPACECRAFT. HOWEVER, CURRENT MEMBRANE MODULE DESIGNS HAVE TWO MAJOR SHORTCOMINGS FOR THIS APPLICATION: (1) THEY ARE EASILY FOULED BY BACTERIA AND SUSPENDED MATTER FOUND IN WASHWATER, AND (2) THEY ARE RELATIVELY HEAVY. THIS EFFORT INVESTIGATES A NEW TYPE OF RO MEMBRAME MODULE BASED ON A TUBE-SIDE-FEED HOLLOW-FIBER MEMBRANE CONFIGURATION THAT OVERCOMES BOTH SHORTCOMINGS. POSITIVE FEED FLOW WITHIN THE HOLLOW-FIBER LUMENS IS EXPECTED TO MINIMIZE FOULING. BECAUSE THE FIBERS THEMSELVES SERVE AS PRESSURE VESSELS, NO HEAVY EXTERNAL PRESSURE VESSEL IS REQUIRED. IT IS ESTIMATED THAT A MODULE OF THIS DESIGN WOULD BE ABOUT 1/16 THE WEIGHT OF A CONVENTIONAL MODULE AND WOULD REQUIRE ABOUT 1/2 THE SPACE. THE PHASE I PROGRAM DEMONSTRATES THE FOULINGRESISTANCE OF THIS MODULE CONFIGURATION DURING PROLONGED TREATMENT OF ACTUAL WASHWATER USING WATER-DESALTING MODULES ALREADY UNDER DEVELOPMENT. A PROTOTYPE LIGHT-WEIGHT , HIGH PRODUCTIVITY MODULE SPECIFICALLY DESIGNED FOR WASHWATER RECYCLING IS CONSTRUCTED AND TESTED. BASED ON THE TECHNICALRESULTS, A DESIGN ANALYSIS OF RO FOR SPACE VEHICLE WASHWATERRECYCLING IS CONDUCTED. | Q715223 | 0.02424 | Sound module | 7 |
000e80047232b2c222bdd84df6731e882a4dd6bd | EXTENDED SPACE MISSIONS REQUIRE EXTENSIVE RECYCLING OF WATERTO PERMIT FREQUENT WASHING AND BATHING OF THE CREW. REVERSEOSMOSIS (RO), OFTEN CALLED HYPERFILTRATION, PROMISES TO BE A UNIQUELY SUITED TECHNOLOGY FOR WATER RECYCLING IN SPACECRAFT. HOWEVER, CURRENT MEMBRANE MODULE DESIGNS HAVE TWO MAJOR SHORTCOMINGS FOR THIS APPLICATION: (1) THEY ARE EASILY FOULED BY BACTERIA AND SUSPENDED MATTER FOUND IN WASHWATER, AND (2) THEY ARE RELATIVELY HEAVY. THIS EFFORT INVESTIGATES A NEW TYPE OF RO MEMBRAME MODULE BASED ON A TUBE-SIDE-FEED HOLLOW-FIBER MEMBRANE CONFIGURATION THAT OVERCOMES BOTH SHORTCOMINGS. POSITIVE FEED FLOW WITHIN THE HOLLOW-FIBER LUMENS IS EXPECTED TO MINIMIZE FOULING. BECAUSE THE FIBERS THEMSELVES SERVE AS PRESSURE VESSELS, NO HEAVY EXTERNAL PRESSURE VESSEL IS REQUIRED. IT IS ESTIMATED THAT A MODULE OF THIS DESIGN WOULD BE ABOUT 1/16 THE WEIGHT OF A CONVENTIONAL MODULE AND WOULD REQUIRE ABOUT 1/2 THE SPACE. THE PHASE I PROGRAM DEMONSTRATES THE FOULINGRESISTANCE OF THIS MODULE CONFIGURATION DURING PROLONGED TREATMENT OF ACTUAL WASHWATER USING WATER-DESALTING MODULES ALREADY UNDER DEVELOPMENT. A PROTOTYPE LIGHT-WEIGHT , HIGH PRODUCTIVITY MODULE SPECIFICALLY DESIGNED FOR WASHWATER RECYCLING IS CONSTRUCTED AND TESTED. BASED ON THE TECHNICALRESULTS, A DESIGN ANALYSIS OF RO FOR SPACE VEHICLE WASHWATERRECYCLING IS CONDUCTED. | Q7070482 | 0.023728 | Nutrient cycle | 8 |
000e80047232b2c222bdd84df6731e882a4dd6bd | EXTENDED SPACE MISSIONS REQUIRE EXTENSIVE RECYCLING OF WATERTO PERMIT FREQUENT WASHING AND BATHING OF THE CREW. REVERSEOSMOSIS (RO), OFTEN CALLED HYPERFILTRATION, PROMISES TO BE A UNIQUELY SUITED TECHNOLOGY FOR WATER RECYCLING IN SPACECRAFT. HOWEVER, CURRENT MEMBRANE MODULE DESIGNS HAVE TWO MAJOR SHORTCOMINGS FOR THIS APPLICATION: (1) THEY ARE EASILY FOULED BY BACTERIA AND SUSPENDED MATTER FOUND IN WASHWATER, AND (2) THEY ARE RELATIVELY HEAVY. THIS EFFORT INVESTIGATES A NEW TYPE OF RO MEMBRAME MODULE BASED ON A TUBE-SIDE-FEED HOLLOW-FIBER MEMBRANE CONFIGURATION THAT OVERCOMES BOTH SHORTCOMINGS. POSITIVE FEED FLOW WITHIN THE HOLLOW-FIBER LUMENS IS EXPECTED TO MINIMIZE FOULING. BECAUSE THE FIBERS THEMSELVES SERVE AS PRESSURE VESSELS, NO HEAVY EXTERNAL PRESSURE VESSEL IS REQUIRED. IT IS ESTIMATED THAT A MODULE OF THIS DESIGN WOULD BE ABOUT 1/16 THE WEIGHT OF A CONVENTIONAL MODULE AND WOULD REQUIRE ABOUT 1/2 THE SPACE. THE PHASE I PROGRAM DEMONSTRATES THE FOULINGRESISTANCE OF THIS MODULE CONFIGURATION DURING PROLONGED TREATMENT OF ACTUAL WASHWATER USING WATER-DESALTING MODULES ALREADY UNDER DEVELOPMENT. A PROTOTYPE LIGHT-WEIGHT , HIGH PRODUCTIVITY MODULE SPECIFICALLY DESIGNED FOR WASHWATER RECYCLING IS CONSTRUCTED AND TESTED. BASED ON THE TECHNICALRESULTS, A DESIGN ANALYSIS OF RO FOR SPACE VEHICLE WASHWATERRECYCLING IS CONDUCTED. | Q774583 | 0.022836 | Solar panel | 9 |
000e80047232b2c222bdd84df6731e882a4dd6bd | EXTENDED SPACE MISSIONS REQUIRE EXTENSIVE RECYCLING OF WATERTO PERMIT FREQUENT WASHING AND BATHING OF THE CREW. REVERSEOSMOSIS (RO), OFTEN CALLED HYPERFILTRATION, PROMISES TO BE A UNIQUELY SUITED TECHNOLOGY FOR WATER RECYCLING IN SPACECRAFT. HOWEVER, CURRENT MEMBRANE MODULE DESIGNS HAVE TWO MAJOR SHORTCOMINGS FOR THIS APPLICATION: (1) THEY ARE EASILY FOULED BY BACTERIA AND SUSPENDED MATTER FOUND IN WASHWATER, AND (2) THEY ARE RELATIVELY HEAVY. THIS EFFORT INVESTIGATES A NEW TYPE OF RO MEMBRAME MODULE BASED ON A TUBE-SIDE-FEED HOLLOW-FIBER MEMBRANE CONFIGURATION THAT OVERCOMES BOTH SHORTCOMINGS. POSITIVE FEED FLOW WITHIN THE HOLLOW-FIBER LUMENS IS EXPECTED TO MINIMIZE FOULING. BECAUSE THE FIBERS THEMSELVES SERVE AS PRESSURE VESSELS, NO HEAVY EXTERNAL PRESSURE VESSEL IS REQUIRED. IT IS ESTIMATED THAT A MODULE OF THIS DESIGN WOULD BE ABOUT 1/16 THE WEIGHT OF A CONVENTIONAL MODULE AND WOULD REQUIRE ABOUT 1/2 THE SPACE. THE PHASE I PROGRAM DEMONSTRATES THE FOULINGRESISTANCE OF THIS MODULE CONFIGURATION DURING PROLONGED TREATMENT OF ACTUAL WASHWATER USING WATER-DESALTING MODULES ALREADY UNDER DEVELOPMENT. A PROTOTYPE LIGHT-WEIGHT , HIGH PRODUCTIVITY MODULE SPECIFICALLY DESIGNED FOR WASHWATER RECYCLING IS CONSTRUCTED AND TESTED. BASED ON THE TECHNICALRESULTS, A DESIGN ANALYSIS OF RO FOR SPACE VEHICLE WASHWATERRECYCLING IS CONDUCTED. | Q11449356 | 0.022227 | Space vehicle | 10 |
000e80047232b2c222bdd84df6731e882a4dd6bd | EXTENDED SPACE MISSIONS REQUIRE EXTENSIVE RECYCLING OF WATERTO PERMIT FREQUENT WASHING AND BATHING OF THE CREW. REVERSEOSMOSIS (RO), OFTEN CALLED HYPERFILTRATION, PROMISES TO BE A UNIQUELY SUITED TECHNOLOGY FOR WATER RECYCLING IN SPACECRAFT. HOWEVER, CURRENT MEMBRANE MODULE DESIGNS HAVE TWO MAJOR SHORTCOMINGS FOR THIS APPLICATION: (1) THEY ARE EASILY FOULED BY BACTERIA AND SUSPENDED MATTER FOUND IN WASHWATER, AND (2) THEY ARE RELATIVELY HEAVY. THIS EFFORT INVESTIGATES A NEW TYPE OF RO MEMBRAME MODULE BASED ON A TUBE-SIDE-FEED HOLLOW-FIBER MEMBRANE CONFIGURATION THAT OVERCOMES BOTH SHORTCOMINGS. POSITIVE FEED FLOW WITHIN THE HOLLOW-FIBER LUMENS IS EXPECTED TO MINIMIZE FOULING. BECAUSE THE FIBERS THEMSELVES SERVE AS PRESSURE VESSELS, NO HEAVY EXTERNAL PRESSURE VESSEL IS REQUIRED. IT IS ESTIMATED THAT A MODULE OF THIS DESIGN WOULD BE ABOUT 1/16 THE WEIGHT OF A CONVENTIONAL MODULE AND WOULD REQUIRE ABOUT 1/2 THE SPACE. THE PHASE I PROGRAM DEMONSTRATES THE FOULINGRESISTANCE OF THIS MODULE CONFIGURATION DURING PROLONGED TREATMENT OF ACTUAL WASHWATER USING WATER-DESALTING MODULES ALREADY UNDER DEVELOPMENT. A PROTOTYPE LIGHT-WEIGHT , HIGH PRODUCTIVITY MODULE SPECIFICALLY DESIGNED FOR WASHWATER RECYCLING IS CONSTRUCTED AND TESTED. BASED ON THE TECHNICALRESULTS, A DESIGN ANALYSIS OF RO FOR SPACE VEHICLE WASHWATERRECYCLING IS CONDUCTED. | Q3243428 | 0.020666 | Computer recycling | 11 |
000e80047232b2c222bdd84df6731e882a4dd6bd | EXTENDED SPACE MISSIONS REQUIRE EXTENSIVE RECYCLING OF WATERTO PERMIT FREQUENT WASHING AND BATHING OF THE CREW. REVERSEOSMOSIS (RO), OFTEN CALLED HYPERFILTRATION, PROMISES TO BE A UNIQUELY SUITED TECHNOLOGY FOR WATER RECYCLING IN SPACECRAFT. HOWEVER, CURRENT MEMBRANE MODULE DESIGNS HAVE TWO MAJOR SHORTCOMINGS FOR THIS APPLICATION: (1) THEY ARE EASILY FOULED BY BACTERIA AND SUSPENDED MATTER FOUND IN WASHWATER, AND (2) THEY ARE RELATIVELY HEAVY. THIS EFFORT INVESTIGATES A NEW TYPE OF RO MEMBRAME MODULE BASED ON A TUBE-SIDE-FEED HOLLOW-FIBER MEMBRANE CONFIGURATION THAT OVERCOMES BOTH SHORTCOMINGS. POSITIVE FEED FLOW WITHIN THE HOLLOW-FIBER LUMENS IS EXPECTED TO MINIMIZE FOULING. BECAUSE THE FIBERS THEMSELVES SERVE AS PRESSURE VESSELS, NO HEAVY EXTERNAL PRESSURE VESSEL IS REQUIRED. IT IS ESTIMATED THAT A MODULE OF THIS DESIGN WOULD BE ABOUT 1/16 THE WEIGHT OF A CONVENTIONAL MODULE AND WOULD REQUIRE ABOUT 1/2 THE SPACE. THE PHASE I PROGRAM DEMONSTRATES THE FOULINGRESISTANCE OF THIS MODULE CONFIGURATION DURING PROLONGED TREATMENT OF ACTUAL WASHWATER USING WATER-DESALTING MODULES ALREADY UNDER DEVELOPMENT. A PROTOTYPE LIGHT-WEIGHT , HIGH PRODUCTIVITY MODULE SPECIFICALLY DESIGNED FOR WASHWATER RECYCLING IS CONSTRUCTED AND TESTED. BASED ON THE TECHNICALRESULTS, A DESIGN ANALYSIS OF RO FOR SPACE VEHICLE WASHWATERRECYCLING IS CONDUCTED. | Q6453666 | 0.019259 | Modular programming | 12 |
000e80047232b2c222bdd84df6731e882a4dd6bd | EXTENDED SPACE MISSIONS REQUIRE EXTENSIVE RECYCLING OF WATERTO PERMIT FREQUENT WASHING AND BATHING OF THE CREW. REVERSEOSMOSIS (RO), OFTEN CALLED HYPERFILTRATION, PROMISES TO BE A UNIQUELY SUITED TECHNOLOGY FOR WATER RECYCLING IN SPACECRAFT. HOWEVER, CURRENT MEMBRANE MODULE DESIGNS HAVE TWO MAJOR SHORTCOMINGS FOR THIS APPLICATION: (1) THEY ARE EASILY FOULED BY BACTERIA AND SUSPENDED MATTER FOUND IN WASHWATER, AND (2) THEY ARE RELATIVELY HEAVY. THIS EFFORT INVESTIGATES A NEW TYPE OF RO MEMBRAME MODULE BASED ON A TUBE-SIDE-FEED HOLLOW-FIBER MEMBRANE CONFIGURATION THAT OVERCOMES BOTH SHORTCOMINGS. POSITIVE FEED FLOW WITHIN THE HOLLOW-FIBER LUMENS IS EXPECTED TO MINIMIZE FOULING. BECAUSE THE FIBERS THEMSELVES SERVE AS PRESSURE VESSELS, NO HEAVY EXTERNAL PRESSURE VESSEL IS REQUIRED. IT IS ESTIMATED THAT A MODULE OF THIS DESIGN WOULD BE ABOUT 1/16 THE WEIGHT OF A CONVENTIONAL MODULE AND WOULD REQUIRE ABOUT 1/2 THE SPACE. THE PHASE I PROGRAM DEMONSTRATES THE FOULINGRESISTANCE OF THIS MODULE CONFIGURATION DURING PROLONGED TREATMENT OF ACTUAL WASHWATER USING WATER-DESALTING MODULES ALREADY UNDER DEVELOPMENT. A PROTOTYPE LIGHT-WEIGHT , HIGH PRODUCTIVITY MODULE SPECIFICALLY DESIGNED FOR WASHWATER RECYCLING IS CONSTRUCTED AND TESTED. BASED ON THE TECHNICALRESULTS, A DESIGN ANALYSIS OF RO FOR SPACE VEHICLE WASHWATERRECYCLING IS CONDUCTED. | Q2918770 | 0.019189 | Shoulder-fired missile | 13 |
000e80047232b2c222bdd84df6731e882a4dd6bd | EXTENDED SPACE MISSIONS REQUIRE EXTENSIVE RECYCLING OF WATERTO PERMIT FREQUENT WASHING AND BATHING OF THE CREW. REVERSEOSMOSIS (RO), OFTEN CALLED HYPERFILTRATION, PROMISES TO BE A UNIQUELY SUITED TECHNOLOGY FOR WATER RECYCLING IN SPACECRAFT. HOWEVER, CURRENT MEMBRANE MODULE DESIGNS HAVE TWO MAJOR SHORTCOMINGS FOR THIS APPLICATION: (1) THEY ARE EASILY FOULED BY BACTERIA AND SUSPENDED MATTER FOUND IN WASHWATER, AND (2) THEY ARE RELATIVELY HEAVY. THIS EFFORT INVESTIGATES A NEW TYPE OF RO MEMBRAME MODULE BASED ON A TUBE-SIDE-FEED HOLLOW-FIBER MEMBRANE CONFIGURATION THAT OVERCOMES BOTH SHORTCOMINGS. POSITIVE FEED FLOW WITHIN THE HOLLOW-FIBER LUMENS IS EXPECTED TO MINIMIZE FOULING. BECAUSE THE FIBERS THEMSELVES SERVE AS PRESSURE VESSELS, NO HEAVY EXTERNAL PRESSURE VESSEL IS REQUIRED. IT IS ESTIMATED THAT A MODULE OF THIS DESIGN WOULD BE ABOUT 1/16 THE WEIGHT OF A CONVENTIONAL MODULE AND WOULD REQUIRE ABOUT 1/2 THE SPACE. THE PHASE I PROGRAM DEMONSTRATES THE FOULINGRESISTANCE OF THIS MODULE CONFIGURATION DURING PROLONGED TREATMENT OF ACTUAL WASHWATER USING WATER-DESALTING MODULES ALREADY UNDER DEVELOPMENT. A PROTOTYPE LIGHT-WEIGHT , HIGH PRODUCTIVITY MODULE SPECIFICALLY DESIGNED FOR WASHWATER RECYCLING IS CONSTRUCTED AND TESTED. BASED ON THE TECHNICALRESULTS, A DESIGN ANALYSIS OF RO FOR SPACE VEHICLE WASHWATERRECYCLING IS CONDUCTED. | Q6661273 | 0.018801 | Vessel | 14 |
000e80047232b2c222bdd84df6731e882a4dd6bd | EXTENDED SPACE MISSIONS REQUIRE EXTENSIVE RECYCLING OF WATERTO PERMIT FREQUENT WASHING AND BATHING OF THE CREW. REVERSEOSMOSIS (RO), OFTEN CALLED HYPERFILTRATION, PROMISES TO BE A UNIQUELY SUITED TECHNOLOGY FOR WATER RECYCLING IN SPACECRAFT. HOWEVER, CURRENT MEMBRANE MODULE DESIGNS HAVE TWO MAJOR SHORTCOMINGS FOR THIS APPLICATION: (1) THEY ARE EASILY FOULED BY BACTERIA AND SUSPENDED MATTER FOUND IN WASHWATER, AND (2) THEY ARE RELATIVELY HEAVY. THIS EFFORT INVESTIGATES A NEW TYPE OF RO MEMBRAME MODULE BASED ON A TUBE-SIDE-FEED HOLLOW-FIBER MEMBRANE CONFIGURATION THAT OVERCOMES BOTH SHORTCOMINGS. POSITIVE FEED FLOW WITHIN THE HOLLOW-FIBER LUMENS IS EXPECTED TO MINIMIZE FOULING. BECAUSE THE FIBERS THEMSELVES SERVE AS PRESSURE VESSELS, NO HEAVY EXTERNAL PRESSURE VESSEL IS REQUIRED. IT IS ESTIMATED THAT A MODULE OF THIS DESIGN WOULD BE ABOUT 1/16 THE WEIGHT OF A CONVENTIONAL MODULE AND WOULD REQUIRE ABOUT 1/2 THE SPACE. THE PHASE I PROGRAM DEMONSTRATES THE FOULINGRESISTANCE OF THIS MODULE CONFIGURATION DURING PROLONGED TREATMENT OF ACTUAL WASHWATER USING WATER-DESALTING MODULES ALREADY UNDER DEVELOPMENT. A PROTOTYPE LIGHT-WEIGHT , HIGH PRODUCTIVITY MODULE SPECIFICALLY DESIGNED FOR WASHWATER RECYCLING IS CONSTRUCTED AND TESTED. BASED ON THE TECHNICALRESULTS, A DESIGN ANALYSIS OF RO FOR SPACE VEHICLE WASHWATERRECYCLING IS CONDUCTED. | Q1145647 | 0.018601 | Paper recycling | 15 |
000e80047232b2c222bdd84df6731e882a4dd6bd | EXTENDED SPACE MISSIONS REQUIRE EXTENSIVE RECYCLING OF WATERTO PERMIT FREQUENT WASHING AND BATHING OF THE CREW. REVERSEOSMOSIS (RO), OFTEN CALLED HYPERFILTRATION, PROMISES TO BE A UNIQUELY SUITED TECHNOLOGY FOR WATER RECYCLING IN SPACECRAFT. HOWEVER, CURRENT MEMBRANE MODULE DESIGNS HAVE TWO MAJOR SHORTCOMINGS FOR THIS APPLICATION: (1) THEY ARE EASILY FOULED BY BACTERIA AND SUSPENDED MATTER FOUND IN WASHWATER, AND (2) THEY ARE RELATIVELY HEAVY. THIS EFFORT INVESTIGATES A NEW TYPE OF RO MEMBRAME MODULE BASED ON A TUBE-SIDE-FEED HOLLOW-FIBER MEMBRANE CONFIGURATION THAT OVERCOMES BOTH SHORTCOMINGS. POSITIVE FEED FLOW WITHIN THE HOLLOW-FIBER LUMENS IS EXPECTED TO MINIMIZE FOULING. BECAUSE THE FIBERS THEMSELVES SERVE AS PRESSURE VESSELS, NO HEAVY EXTERNAL PRESSURE VESSEL IS REQUIRED. IT IS ESTIMATED THAT A MODULE OF THIS DESIGN WOULD BE ABOUT 1/16 THE WEIGHT OF A CONVENTIONAL MODULE AND WOULD REQUIRE ABOUT 1/2 THE SPACE. THE PHASE I PROGRAM DEMONSTRATES THE FOULINGRESISTANCE OF THIS MODULE CONFIGURATION DURING PROLONGED TREATMENT OF ACTUAL WASHWATER USING WATER-DESALTING MODULES ALREADY UNDER DEVELOPMENT. A PROTOTYPE LIGHT-WEIGHT , HIGH PRODUCTIVITY MODULE SPECIFICALLY DESIGNED FOR WASHWATER RECYCLING IS CONSTRUCTED AND TESTED. BASED ON THE TECHNICALRESULTS, A DESIGN ANALYSIS OF RO FOR SPACE VEHICLE WASHWATERRECYCLING IS CONDUCTED. | Q1194111 | 0.018387 | Plastic recycling | 16 |
000e80047232b2c222bdd84df6731e882a4dd6bd | EXTENDED SPACE MISSIONS REQUIRE EXTENSIVE RECYCLING OF WATERTO PERMIT FREQUENT WASHING AND BATHING OF THE CREW. REVERSEOSMOSIS (RO), OFTEN CALLED HYPERFILTRATION, PROMISES TO BE A UNIQUELY SUITED TECHNOLOGY FOR WATER RECYCLING IN SPACECRAFT. HOWEVER, CURRENT MEMBRANE MODULE DESIGNS HAVE TWO MAJOR SHORTCOMINGS FOR THIS APPLICATION: (1) THEY ARE EASILY FOULED BY BACTERIA AND SUSPENDED MATTER FOUND IN WASHWATER, AND (2) THEY ARE RELATIVELY HEAVY. THIS EFFORT INVESTIGATES A NEW TYPE OF RO MEMBRAME MODULE BASED ON A TUBE-SIDE-FEED HOLLOW-FIBER MEMBRANE CONFIGURATION THAT OVERCOMES BOTH SHORTCOMINGS. POSITIVE FEED FLOW WITHIN THE HOLLOW-FIBER LUMENS IS EXPECTED TO MINIMIZE FOULING. BECAUSE THE FIBERS THEMSELVES SERVE AS PRESSURE VESSELS, NO HEAVY EXTERNAL PRESSURE VESSEL IS REQUIRED. IT IS ESTIMATED THAT A MODULE OF THIS DESIGN WOULD BE ABOUT 1/16 THE WEIGHT OF A CONVENTIONAL MODULE AND WOULD REQUIRE ABOUT 1/2 THE SPACE. THE PHASE I PROGRAM DEMONSTRATES THE FOULINGRESISTANCE OF THIS MODULE CONFIGURATION DURING PROLONGED TREATMENT OF ACTUAL WASHWATER USING WATER-DESALTING MODULES ALREADY UNDER DEVELOPMENT. A PROTOTYPE LIGHT-WEIGHT , HIGH PRODUCTIVITY MODULE SPECIFICALLY DESIGNED FOR WASHWATER RECYCLING IS CONSTRUCTED AND TESTED. BASED ON THE TECHNICALRESULTS, A DESIGN ANALYSIS OF RO FOR SPACE VEHICLE WASHWATERRECYCLING IS CONDUCTED. | Q810941 | 0.017989 | Battery recycling | 17 |
000e80047232b2c222bdd84df6731e882a4dd6bd | EXTENDED SPACE MISSIONS REQUIRE EXTENSIVE RECYCLING OF WATERTO PERMIT FREQUENT WASHING AND BATHING OF THE CREW. REVERSEOSMOSIS (RO), OFTEN CALLED HYPERFILTRATION, PROMISES TO BE A UNIQUELY SUITED TECHNOLOGY FOR WATER RECYCLING IN SPACECRAFT. HOWEVER, CURRENT MEMBRANE MODULE DESIGNS HAVE TWO MAJOR SHORTCOMINGS FOR THIS APPLICATION: (1) THEY ARE EASILY FOULED BY BACTERIA AND SUSPENDED MATTER FOUND IN WASHWATER, AND (2) THEY ARE RELATIVELY HEAVY. THIS EFFORT INVESTIGATES A NEW TYPE OF RO MEMBRAME MODULE BASED ON A TUBE-SIDE-FEED HOLLOW-FIBER MEMBRANE CONFIGURATION THAT OVERCOMES BOTH SHORTCOMINGS. POSITIVE FEED FLOW WITHIN THE HOLLOW-FIBER LUMENS IS EXPECTED TO MINIMIZE FOULING. BECAUSE THE FIBERS THEMSELVES SERVE AS PRESSURE VESSELS, NO HEAVY EXTERNAL PRESSURE VESSEL IS REQUIRED. IT IS ESTIMATED THAT A MODULE OF THIS DESIGN WOULD BE ABOUT 1/16 THE WEIGHT OF A CONVENTIONAL MODULE AND WOULD REQUIRE ABOUT 1/2 THE SPACE. THE PHASE I PROGRAM DEMONSTRATES THE FOULINGRESISTANCE OF THIS MODULE CONFIGURATION DURING PROLONGED TREATMENT OF ACTUAL WASHWATER USING WATER-DESALTING MODULES ALREADY UNDER DEVELOPMENT. A PROTOTYPE LIGHT-WEIGHT , HIGH PRODUCTIVITY MODULE SPECIFICALLY DESIGNED FOR WASHWATER RECYCLING IS CONSTRUCTED AND TESTED. BASED ON THE TECHNICALRESULTS, A DESIGN ANALYSIS OF RO FOR SPACE VEHICLE WASHWATERRECYCLING IS CONDUCTED. | Q1392857 | 0.016857 | Vehicle recycling | 18 |
000e80047232b2c222bdd84df6731e882a4dd6bd | EXTENDED SPACE MISSIONS REQUIRE EXTENSIVE RECYCLING OF WATERTO PERMIT FREQUENT WASHING AND BATHING OF THE CREW. REVERSEOSMOSIS (RO), OFTEN CALLED HYPERFILTRATION, PROMISES TO BE A UNIQUELY SUITED TECHNOLOGY FOR WATER RECYCLING IN SPACECRAFT. HOWEVER, CURRENT MEMBRANE MODULE DESIGNS HAVE TWO MAJOR SHORTCOMINGS FOR THIS APPLICATION: (1) THEY ARE EASILY FOULED BY BACTERIA AND SUSPENDED MATTER FOUND IN WASHWATER, AND (2) THEY ARE RELATIVELY HEAVY. THIS EFFORT INVESTIGATES A NEW TYPE OF RO MEMBRAME MODULE BASED ON A TUBE-SIDE-FEED HOLLOW-FIBER MEMBRANE CONFIGURATION THAT OVERCOMES BOTH SHORTCOMINGS. POSITIVE FEED FLOW WITHIN THE HOLLOW-FIBER LUMENS IS EXPECTED TO MINIMIZE FOULING. BECAUSE THE FIBERS THEMSELVES SERVE AS PRESSURE VESSELS, NO HEAVY EXTERNAL PRESSURE VESSEL IS REQUIRED. IT IS ESTIMATED THAT A MODULE OF THIS DESIGN WOULD BE ABOUT 1/16 THE WEIGHT OF A CONVENTIONAL MODULE AND WOULD REQUIRE ABOUT 1/2 THE SPACE. THE PHASE I PROGRAM DEMONSTRATES THE FOULINGRESISTANCE OF THIS MODULE CONFIGURATION DURING PROLONGED TREATMENT OF ACTUAL WASHWATER USING WATER-DESALTING MODULES ALREADY UNDER DEVELOPMENT. A PROTOTYPE LIGHT-WEIGHT , HIGH PRODUCTIVITY MODULE SPECIFICALLY DESIGNED FOR WASHWATER RECYCLING IS CONSTRUCTED AND TESTED. BASED ON THE TECHNICALRESULTS, A DESIGN ANALYSIS OF RO FOR SPACE VEHICLE WASHWATERRECYCLING IS CONDUCTED. | Q25271 | 0.015394 | International Space Station | 19 |
000e80047232b2c222bdd84df6731e882a4dd6bd | EXTENDED SPACE MISSIONS REQUIRE EXTENSIVE RECYCLING OF WATERTO PERMIT FREQUENT WASHING AND BATHING OF THE CREW. REVERSEOSMOSIS (RO), OFTEN CALLED HYPERFILTRATION, PROMISES TO BE A UNIQUELY SUITED TECHNOLOGY FOR WATER RECYCLING IN SPACECRAFT. HOWEVER, CURRENT MEMBRANE MODULE DESIGNS HAVE TWO MAJOR SHORTCOMINGS FOR THIS APPLICATION: (1) THEY ARE EASILY FOULED BY BACTERIA AND SUSPENDED MATTER FOUND IN WASHWATER, AND (2) THEY ARE RELATIVELY HEAVY. THIS EFFORT INVESTIGATES A NEW TYPE OF RO MEMBRAME MODULE BASED ON A TUBE-SIDE-FEED HOLLOW-FIBER MEMBRANE CONFIGURATION THAT OVERCOMES BOTH SHORTCOMINGS. POSITIVE FEED FLOW WITHIN THE HOLLOW-FIBER LUMENS IS EXPECTED TO MINIMIZE FOULING. BECAUSE THE FIBERS THEMSELVES SERVE AS PRESSURE VESSELS, NO HEAVY EXTERNAL PRESSURE VESSEL IS REQUIRED. IT IS ESTIMATED THAT A MODULE OF THIS DESIGN WOULD BE ABOUT 1/16 THE WEIGHT OF A CONVENTIONAL MODULE AND WOULD REQUIRE ABOUT 1/2 THE SPACE. THE PHASE I PROGRAM DEMONSTRATES THE FOULINGRESISTANCE OF THIS MODULE CONFIGURATION DURING PROLONGED TREATMENT OF ACTUAL WASHWATER USING WATER-DESALTING MODULES ALREADY UNDER DEVELOPMENT. A PROTOTYPE LIGHT-WEIGHT , HIGH PRODUCTIVITY MODULE SPECIFICALLY DESIGNED FOR WASHWATER RECYCLING IS CONSTRUCTED AND TESTED. BASED ON THE TECHNICALRESULTS, A DESIGN ANALYSIS OF RO FOR SPACE VEHICLE WASHWATERRECYCLING IS CONDUCTED. | Q39552 | 0.015384 | Pressure | 20 |
000e80047232b2c222bdd84df6731e882a4dd6bd | EXTENDED SPACE MISSIONS REQUIRE EXTENSIVE RECYCLING OF WATERTO PERMIT FREQUENT WASHING AND BATHING OF THE CREW. REVERSEOSMOSIS (RO), OFTEN CALLED HYPERFILTRATION, PROMISES TO BE A UNIQUELY SUITED TECHNOLOGY FOR WATER RECYCLING IN SPACECRAFT. HOWEVER, CURRENT MEMBRANE MODULE DESIGNS HAVE TWO MAJOR SHORTCOMINGS FOR THIS APPLICATION: (1) THEY ARE EASILY FOULED BY BACTERIA AND SUSPENDED MATTER FOUND IN WASHWATER, AND (2) THEY ARE RELATIVELY HEAVY. THIS EFFORT INVESTIGATES A NEW TYPE OF RO MEMBRAME MODULE BASED ON A TUBE-SIDE-FEED HOLLOW-FIBER MEMBRANE CONFIGURATION THAT OVERCOMES BOTH SHORTCOMINGS. POSITIVE FEED FLOW WITHIN THE HOLLOW-FIBER LUMENS IS EXPECTED TO MINIMIZE FOULING. BECAUSE THE FIBERS THEMSELVES SERVE AS PRESSURE VESSELS, NO HEAVY EXTERNAL PRESSURE VESSEL IS REQUIRED. IT IS ESTIMATED THAT A MODULE OF THIS DESIGN WOULD BE ABOUT 1/16 THE WEIGHT OF A CONVENTIONAL MODULE AND WOULD REQUIRE ABOUT 1/2 THE SPACE. THE PHASE I PROGRAM DEMONSTRATES THE FOULINGRESISTANCE OF THIS MODULE CONFIGURATION DURING PROLONGED TREATMENT OF ACTUAL WASHWATER USING WATER-DESALTING MODULES ALREADY UNDER DEVELOPMENT. A PROTOTYPE LIGHT-WEIGHT , HIGH PRODUCTIVITY MODULE SPECIFICALLY DESIGNED FOR WASHWATER RECYCLING IS CONSTRUCTED AND TESTED. BASED ON THE TECHNICALRESULTS, A DESIGN ANALYSIS OF RO FOR SPACE VEHICLE WASHWATERRECYCLING IS CONDUCTED. | Q1739331 | 0.014891 | Loadable kernel module | 21 |
000e80047232b2c222bdd84df6731e882a4dd6bd | EXTENDED SPACE MISSIONS REQUIRE EXTENSIVE RECYCLING OF WATERTO PERMIT FREQUENT WASHING AND BATHING OF THE CREW. REVERSEOSMOSIS (RO), OFTEN CALLED HYPERFILTRATION, PROMISES TO BE A UNIQUELY SUITED TECHNOLOGY FOR WATER RECYCLING IN SPACECRAFT. HOWEVER, CURRENT MEMBRANE MODULE DESIGNS HAVE TWO MAJOR SHORTCOMINGS FOR THIS APPLICATION: (1) THEY ARE EASILY FOULED BY BACTERIA AND SUSPENDED MATTER FOUND IN WASHWATER, AND (2) THEY ARE RELATIVELY HEAVY. THIS EFFORT INVESTIGATES A NEW TYPE OF RO MEMBRAME MODULE BASED ON A TUBE-SIDE-FEED HOLLOW-FIBER MEMBRANE CONFIGURATION THAT OVERCOMES BOTH SHORTCOMINGS. POSITIVE FEED FLOW WITHIN THE HOLLOW-FIBER LUMENS IS EXPECTED TO MINIMIZE FOULING. BECAUSE THE FIBERS THEMSELVES SERVE AS PRESSURE VESSELS, NO HEAVY EXTERNAL PRESSURE VESSEL IS REQUIRED. IT IS ESTIMATED THAT A MODULE OF THIS DESIGN WOULD BE ABOUT 1/16 THE WEIGHT OF A CONVENTIONAL MODULE AND WOULD REQUIRE ABOUT 1/2 THE SPACE. THE PHASE I PROGRAM DEMONSTRATES THE FOULINGRESISTANCE OF THIS MODULE CONFIGURATION DURING PROLONGED TREATMENT OF ACTUAL WASHWATER USING WATER-DESALTING MODULES ALREADY UNDER DEVELOPMENT. A PROTOTYPE LIGHT-WEIGHT , HIGH PRODUCTIVITY MODULE SPECIFICALLY DESIGNED FOR WASHWATER RECYCLING IS CONSTRUCTED AND TESTED. BASED ON THE TECHNICALRESULTS, A DESIGN ANALYSIS OF RO FOR SPACE VEHICLE WASHWATERRECYCLING IS CONDUCTED. | Q1201871 | 0.014301 | Platform supply vessel | 22 |
000e80047232b2c222bdd84df6731e882a4dd6bd | EXTENDED SPACE MISSIONS REQUIRE EXTENSIVE RECYCLING OF WATERTO PERMIT FREQUENT WASHING AND BATHING OF THE CREW. REVERSEOSMOSIS (RO), OFTEN CALLED HYPERFILTRATION, PROMISES TO BE A UNIQUELY SUITED TECHNOLOGY FOR WATER RECYCLING IN SPACECRAFT. HOWEVER, CURRENT MEMBRANE MODULE DESIGNS HAVE TWO MAJOR SHORTCOMINGS FOR THIS APPLICATION: (1) THEY ARE EASILY FOULED BY BACTERIA AND SUSPENDED MATTER FOUND IN WASHWATER, AND (2) THEY ARE RELATIVELY HEAVY. THIS EFFORT INVESTIGATES A NEW TYPE OF RO MEMBRAME MODULE BASED ON A TUBE-SIDE-FEED HOLLOW-FIBER MEMBRANE CONFIGURATION THAT OVERCOMES BOTH SHORTCOMINGS. POSITIVE FEED FLOW WITHIN THE HOLLOW-FIBER LUMENS IS EXPECTED TO MINIMIZE FOULING. BECAUSE THE FIBERS THEMSELVES SERVE AS PRESSURE VESSELS, NO HEAVY EXTERNAL PRESSURE VESSEL IS REQUIRED. IT IS ESTIMATED THAT A MODULE OF THIS DESIGN WOULD BE ABOUT 1/16 THE WEIGHT OF A CONVENTIONAL MODULE AND WOULD REQUIRE ABOUT 1/2 THE SPACE. THE PHASE I PROGRAM DEMONSTRATES THE FOULINGRESISTANCE OF THIS MODULE CONFIGURATION DURING PROLONGED TREATMENT OF ACTUAL WASHWATER USING WATER-DESALTING MODULES ALREADY UNDER DEVELOPMENT. A PROTOTYPE LIGHT-WEIGHT , HIGH PRODUCTIVITY MODULE SPECIFICALLY DESIGNED FOR WASHWATER RECYCLING IS CONSTRUCTED AND TESTED. BASED ON THE TECHNICALRESULTS, A DESIGN ANALYSIS OF RO FOR SPACE VEHICLE WASHWATERRECYCLING IS CONDUCTED. | Q81809 | 0.013581 | Atmospheric pressure | 23 |
000e80047232b2c222bdd84df6731e882a4dd6bd | EXTENDED SPACE MISSIONS REQUIRE EXTENSIVE RECYCLING OF WATERTO PERMIT FREQUENT WASHING AND BATHING OF THE CREW. REVERSEOSMOSIS (RO), OFTEN CALLED HYPERFILTRATION, PROMISES TO BE A UNIQUELY SUITED TECHNOLOGY FOR WATER RECYCLING IN SPACECRAFT. HOWEVER, CURRENT MEMBRANE MODULE DESIGNS HAVE TWO MAJOR SHORTCOMINGS FOR THIS APPLICATION: (1) THEY ARE EASILY FOULED BY BACTERIA AND SUSPENDED MATTER FOUND IN WASHWATER, AND (2) THEY ARE RELATIVELY HEAVY. THIS EFFORT INVESTIGATES A NEW TYPE OF RO MEMBRAME MODULE BASED ON A TUBE-SIDE-FEED HOLLOW-FIBER MEMBRANE CONFIGURATION THAT OVERCOMES BOTH SHORTCOMINGS. POSITIVE FEED FLOW WITHIN THE HOLLOW-FIBER LUMENS IS EXPECTED TO MINIMIZE FOULING. BECAUSE THE FIBERS THEMSELVES SERVE AS PRESSURE VESSELS, NO HEAVY EXTERNAL PRESSURE VESSEL IS REQUIRED. IT IS ESTIMATED THAT A MODULE OF THIS DESIGN WOULD BE ABOUT 1/16 THE WEIGHT OF A CONVENTIONAL MODULE AND WOULD REQUIRE ABOUT 1/2 THE SPACE. THE PHASE I PROGRAM DEMONSTRATES THE FOULINGRESISTANCE OF THIS MODULE CONFIGURATION DURING PROLONGED TREATMENT OF ACTUAL WASHWATER USING WATER-DESALTING MODULES ALREADY UNDER DEVELOPMENT. A PROTOTYPE LIGHT-WEIGHT , HIGH PRODUCTIVITY MODULE SPECIFICALLY DESIGNED FOR WASHWATER RECYCLING IS CONSTRUCTED AND TESTED. BASED ON THE TECHNICALRESULTS, A DESIGN ANALYSIS OF RO FOR SPACE VEHICLE WASHWATERRECYCLING IS CONDUCTED. | Q1261040 | 0.013569 | Pressure sensor | 24 |
000e80047232b2c222bdd84df6731e882a4dd6bd | EXTENDED SPACE MISSIONS REQUIRE EXTENSIVE RECYCLING OF WATERTO PERMIT FREQUENT WASHING AND BATHING OF THE CREW. REVERSEOSMOSIS (RO), OFTEN CALLED HYPERFILTRATION, PROMISES TO BE A UNIQUELY SUITED TECHNOLOGY FOR WATER RECYCLING IN SPACECRAFT. HOWEVER, CURRENT MEMBRANE MODULE DESIGNS HAVE TWO MAJOR SHORTCOMINGS FOR THIS APPLICATION: (1) THEY ARE EASILY FOULED BY BACTERIA AND SUSPENDED MATTER FOUND IN WASHWATER, AND (2) THEY ARE RELATIVELY HEAVY. THIS EFFORT INVESTIGATES A NEW TYPE OF RO MEMBRAME MODULE BASED ON A TUBE-SIDE-FEED HOLLOW-FIBER MEMBRANE CONFIGURATION THAT OVERCOMES BOTH SHORTCOMINGS. POSITIVE FEED FLOW WITHIN THE HOLLOW-FIBER LUMENS IS EXPECTED TO MINIMIZE FOULING. BECAUSE THE FIBERS THEMSELVES SERVE AS PRESSURE VESSELS, NO HEAVY EXTERNAL PRESSURE VESSEL IS REQUIRED. IT IS ESTIMATED THAT A MODULE OF THIS DESIGN WOULD BE ABOUT 1/16 THE WEIGHT OF A CONVENTIONAL MODULE AND WOULD REQUIRE ABOUT 1/2 THE SPACE. THE PHASE I PROGRAM DEMONSTRATES THE FOULINGRESISTANCE OF THIS MODULE CONFIGURATION DURING PROLONGED TREATMENT OF ACTUAL WASHWATER USING WATER-DESALTING MODULES ALREADY UNDER DEVELOPMENT. A PROTOTYPE LIGHT-WEIGHT , HIGH PRODUCTIVITY MODULE SPECIFICALLY DESIGNED FOR WASHWATER RECYCLING IS CONSTRUCTED AND TESTED. BASED ON THE TECHNICALRESULTS, A DESIGN ANALYSIS OF RO FOR SPACE VEHICLE WASHWATERRECYCLING IS CONDUCTED. | Q912009 | 0.013277 | Modularity | 25 |
000e80047232b2c222bdd84df6731e882a4dd6bd | EXTENDED SPACE MISSIONS REQUIRE EXTENSIVE RECYCLING OF WATERTO PERMIT FREQUENT WASHING AND BATHING OF THE CREW. REVERSEOSMOSIS (RO), OFTEN CALLED HYPERFILTRATION, PROMISES TO BE A UNIQUELY SUITED TECHNOLOGY FOR WATER RECYCLING IN SPACECRAFT. HOWEVER, CURRENT MEMBRANE MODULE DESIGNS HAVE TWO MAJOR SHORTCOMINGS FOR THIS APPLICATION: (1) THEY ARE EASILY FOULED BY BACTERIA AND SUSPENDED MATTER FOUND IN WASHWATER, AND (2) THEY ARE RELATIVELY HEAVY. THIS EFFORT INVESTIGATES A NEW TYPE OF RO MEMBRAME MODULE BASED ON A TUBE-SIDE-FEED HOLLOW-FIBER MEMBRANE CONFIGURATION THAT OVERCOMES BOTH SHORTCOMINGS. POSITIVE FEED FLOW WITHIN THE HOLLOW-FIBER LUMENS IS EXPECTED TO MINIMIZE FOULING. BECAUSE THE FIBERS THEMSELVES SERVE AS PRESSURE VESSELS, NO HEAVY EXTERNAL PRESSURE VESSEL IS REQUIRED. IT IS ESTIMATED THAT A MODULE OF THIS DESIGN WOULD BE ABOUT 1/16 THE WEIGHT OF A CONVENTIONAL MODULE AND WOULD REQUIRE ABOUT 1/2 THE SPACE. THE PHASE I PROGRAM DEMONSTRATES THE FOULINGRESISTANCE OF THIS MODULE CONFIGURATION DURING PROLONGED TREATMENT OF ACTUAL WASHWATER USING WATER-DESALTING MODULES ALREADY UNDER DEVELOPMENT. A PROTOTYPE LIGHT-WEIGHT , HIGH PRODUCTIVITY MODULE SPECIFICALLY DESIGNED FOR WASHWATER RECYCLING IS CONSTRUCTED AND TESTED. BASED ON THE TECHNICALRESULTS, A DESIGN ANALYSIS OF RO FOR SPACE VEHICLE WASHWATERRECYCLING IS CONDUCTED. | Q5227292 | 0.013123 | Data feed | 26 |
000e80047232b2c222bdd84df6731e882a4dd6bd | EXTENDED SPACE MISSIONS REQUIRE EXTENSIVE RECYCLING OF WATERTO PERMIT FREQUENT WASHING AND BATHING OF THE CREW. REVERSEOSMOSIS (RO), OFTEN CALLED HYPERFILTRATION, PROMISES TO BE A UNIQUELY SUITED TECHNOLOGY FOR WATER RECYCLING IN SPACECRAFT. HOWEVER, CURRENT MEMBRANE MODULE DESIGNS HAVE TWO MAJOR SHORTCOMINGS FOR THIS APPLICATION: (1) THEY ARE EASILY FOULED BY BACTERIA AND SUSPENDED MATTER FOUND IN WASHWATER, AND (2) THEY ARE RELATIVELY HEAVY. THIS EFFORT INVESTIGATES A NEW TYPE OF RO MEMBRAME MODULE BASED ON A TUBE-SIDE-FEED HOLLOW-FIBER MEMBRANE CONFIGURATION THAT OVERCOMES BOTH SHORTCOMINGS. POSITIVE FEED FLOW WITHIN THE HOLLOW-FIBER LUMENS IS EXPECTED TO MINIMIZE FOULING. BECAUSE THE FIBERS THEMSELVES SERVE AS PRESSURE VESSELS, NO HEAVY EXTERNAL PRESSURE VESSEL IS REQUIRED. IT IS ESTIMATED THAT A MODULE OF THIS DESIGN WOULD BE ABOUT 1/16 THE WEIGHT OF A CONVENTIONAL MODULE AND WOULD REQUIRE ABOUT 1/2 THE SPACE. THE PHASE I PROGRAM DEMONSTRATES THE FOULINGRESISTANCE OF THIS MODULE CONFIGURATION DURING PROLONGED TREATMENT OF ACTUAL WASHWATER USING WATER-DESALTING MODULES ALREADY UNDER DEVELOPMENT. A PROTOTYPE LIGHT-WEIGHT , HIGH PRODUCTIVITY MODULE SPECIFICALLY DESIGNED FOR WASHWATER RECYCLING IS CONSTRUCTED AND TESTED. BASED ON THE TECHNICALRESULTS, A DESIGN ANALYSIS OF RO FOR SPACE VEHICLE WASHWATERRECYCLING IS CONDUCTED. | Q161 | 0.012603 | Fiber | 27 |
000e80047232b2c222bdd84df6731e882a4dd6bd | EXTENDED SPACE MISSIONS REQUIRE EXTENSIVE RECYCLING OF WATERTO PERMIT FREQUENT WASHING AND BATHING OF THE CREW. REVERSEOSMOSIS (RO), OFTEN CALLED HYPERFILTRATION, PROMISES TO BE A UNIQUELY SUITED TECHNOLOGY FOR WATER RECYCLING IN SPACECRAFT. HOWEVER, CURRENT MEMBRANE MODULE DESIGNS HAVE TWO MAJOR SHORTCOMINGS FOR THIS APPLICATION: (1) THEY ARE EASILY FOULED BY BACTERIA AND SUSPENDED MATTER FOUND IN WASHWATER, AND (2) THEY ARE RELATIVELY HEAVY. THIS EFFORT INVESTIGATES A NEW TYPE OF RO MEMBRAME MODULE BASED ON A TUBE-SIDE-FEED HOLLOW-FIBER MEMBRANE CONFIGURATION THAT OVERCOMES BOTH SHORTCOMINGS. POSITIVE FEED FLOW WITHIN THE HOLLOW-FIBER LUMENS IS EXPECTED TO MINIMIZE FOULING. BECAUSE THE FIBERS THEMSELVES SERVE AS PRESSURE VESSELS, NO HEAVY EXTERNAL PRESSURE VESSEL IS REQUIRED. IT IS ESTIMATED THAT A MODULE OF THIS DESIGN WOULD BE ABOUT 1/16 THE WEIGHT OF A CONVENTIONAL MODULE AND WOULD REQUIRE ABOUT 1/2 THE SPACE. THE PHASE I PROGRAM DEMONSTRATES THE FOULINGRESISTANCE OF THIS MODULE CONFIGURATION DURING PROLONGED TREATMENT OF ACTUAL WASHWATER USING WATER-DESALTING MODULES ALREADY UNDER DEVELOPMENT. A PROTOTYPE LIGHT-WEIGHT , HIGH PRODUCTIVITY MODULE SPECIFICALLY DESIGNED FOR WASHWATER RECYCLING IS CONSTRUCTED AND TESTED. BASED ON THE TECHNICALRESULTS, A DESIGN ANALYSIS OF RO FOR SPACE VEHICLE WASHWATERRECYCLING IS CONDUCTED. | Q17105199 | 0.012593 | Environment Modules (software) | 28 |
000e80047232b2c222bdd84df6731e882a4dd6bd | EXTENDED SPACE MISSIONS REQUIRE EXTENSIVE RECYCLING OF WATERTO PERMIT FREQUENT WASHING AND BATHING OF THE CREW. REVERSEOSMOSIS (RO), OFTEN CALLED HYPERFILTRATION, PROMISES TO BE A UNIQUELY SUITED TECHNOLOGY FOR WATER RECYCLING IN SPACECRAFT. HOWEVER, CURRENT MEMBRANE MODULE DESIGNS HAVE TWO MAJOR SHORTCOMINGS FOR THIS APPLICATION: (1) THEY ARE EASILY FOULED BY BACTERIA AND SUSPENDED MATTER FOUND IN WASHWATER, AND (2) THEY ARE RELATIVELY HEAVY. THIS EFFORT INVESTIGATES A NEW TYPE OF RO MEMBRAME MODULE BASED ON A TUBE-SIDE-FEED HOLLOW-FIBER MEMBRANE CONFIGURATION THAT OVERCOMES BOTH SHORTCOMINGS. POSITIVE FEED FLOW WITHIN THE HOLLOW-FIBER LUMENS IS EXPECTED TO MINIMIZE FOULING. BECAUSE THE FIBERS THEMSELVES SERVE AS PRESSURE VESSELS, NO HEAVY EXTERNAL PRESSURE VESSEL IS REQUIRED. IT IS ESTIMATED THAT A MODULE OF THIS DESIGN WOULD BE ABOUT 1/16 THE WEIGHT OF A CONVENTIONAL MODULE AND WOULD REQUIRE ABOUT 1/2 THE SPACE. THE PHASE I PROGRAM DEMONSTRATES THE FOULINGRESISTANCE OF THIS MODULE CONFIGURATION DURING PROLONGED TREATMENT OF ACTUAL WASHWATER USING WATER-DESALTING MODULES ALREADY UNDER DEVELOPMENT. A PROTOTYPE LIGHT-WEIGHT , HIGH PRODUCTIVITY MODULE SPECIFICALLY DESIGNED FOR WASHWATER RECYCLING IS CONSTRUCTED AND TESTED. BASED ON THE TECHNICALRESULTS, A DESIGN ANALYSIS OF RO FOR SPACE VEHICLE WASHWATERRECYCLING IS CONDUCTED. | Q6889712 | 0.012483 | Modular decomposition | 29 |
000e80047232b2c222bdd84df6731e882a4dd6bd | EXTENDED SPACE MISSIONS REQUIRE EXTENSIVE RECYCLING OF WATERTO PERMIT FREQUENT WASHING AND BATHING OF THE CREW. REVERSEOSMOSIS (RO), OFTEN CALLED HYPERFILTRATION, PROMISES TO BE A UNIQUELY SUITED TECHNOLOGY FOR WATER RECYCLING IN SPACECRAFT. HOWEVER, CURRENT MEMBRANE MODULE DESIGNS HAVE TWO MAJOR SHORTCOMINGS FOR THIS APPLICATION: (1) THEY ARE EASILY FOULED BY BACTERIA AND SUSPENDED MATTER FOUND IN WASHWATER, AND (2) THEY ARE RELATIVELY HEAVY. THIS EFFORT INVESTIGATES A NEW TYPE OF RO MEMBRAME MODULE BASED ON A TUBE-SIDE-FEED HOLLOW-FIBER MEMBRANE CONFIGURATION THAT OVERCOMES BOTH SHORTCOMINGS. POSITIVE FEED FLOW WITHIN THE HOLLOW-FIBER LUMENS IS EXPECTED TO MINIMIZE FOULING. BECAUSE THE FIBERS THEMSELVES SERVE AS PRESSURE VESSELS, NO HEAVY EXTERNAL PRESSURE VESSEL IS REQUIRED. IT IS ESTIMATED THAT A MODULE OF THIS DESIGN WOULD BE ABOUT 1/16 THE WEIGHT OF A CONVENTIONAL MODULE AND WOULD REQUIRE ABOUT 1/2 THE SPACE. THE PHASE I PROGRAM DEMONSTRATES THE FOULINGRESISTANCE OF THIS MODULE CONFIGURATION DURING PROLONGED TREATMENT OF ACTUAL WASHWATER USING WATER-DESALTING MODULES ALREADY UNDER DEVELOPMENT. A PROTOTYPE LIGHT-WEIGHT , HIGH PRODUCTIVITY MODULE SPECIFICALLY DESIGNED FOR WASHWATER RECYCLING IS CONSTRUCTED AND TESTED. BASED ON THE TECHNICALRESULTS, A DESIGN ANALYSIS OF RO FOR SPACE VEHICLE WASHWATERRECYCLING IS CONDUCTED. | Q988343 | 0.012145 | Blood vessel | 30 |
0010ba9fc8850d94dbbaf1f967bfa36e99369fdb | A MMW POLARIZATION DIVERSE TRANSCEIVER SYSTEM PROVIDING BASE BAND FOUR PLANE MONOPULSE, DYNAMICALLY ADJUSTABLE NULLS & POLARIZATION | Q228558 | 0.041055 | Polarization | 1 |
0010ba9fc8850d94dbbaf1f967bfa36e99369fdb | A MMW POLARIZATION DIVERSE TRANSCEIVER SYSTEM PROVIDING BASE BAND FOUR PLANE MONOPULSE, DYNAMICALLY ADJUSTABLE NULLS & POLARIZATION | Q3394057 | 0.036551 | Polarization in astronomy | 2 |
0010ba9fc8850d94dbbaf1f967bfa36e99369fdb | A MMW POLARIZATION DIVERSE TRANSCEIVER SYSTEM PROVIDING BASE BAND FOUR PLANE MONOPULSE, DYNAMICALLY ADJUSTABLE NULLS & POLARIZATION | Q193760 | 0.034829 | Polarization (waves) | 3 |
0010ba9fc8850d94dbbaf1f967bfa36e99369fdb | A MMW POLARIZATION DIVERSE TRANSCEIVER SYSTEM PROVIDING BASE BAND FOUR PLANE MONOPULSE, DYNAMICALLY ADJUSTABLE NULLS & POLARIZATION | Q1551060 | 0.028335 | Group polarization | 4 |
0010ba9fc8850d94dbbaf1f967bfa36e99369fdb | A MMW POLARIZATION DIVERSE TRANSCEIVER SYSTEM PROVIDING BASE BAND FOUR PLANE MONOPULSE, DYNAMICALLY ADJUSTABLE NULLS & POLARIZATION | Q5367036 | 0.021755 | Social polarization | 5 |
0010ba9fc8850d94dbbaf1f967bfa36e99369fdb | A MMW POLARIZATION DIVERSE TRANSCEIVER SYSTEM PROVIDING BASE BAND FOUR PLANE MONOPULSE, DYNAMICALLY ADJUSTABLE NULLS & POLARIZATION | Q6553479 | 0.02021 | Linear polarization | 6 |
0010ba9fc8850d94dbbaf1f967bfa36e99369fdb | A MMW POLARIZATION DIVERSE TRANSCEIVER SYSTEM PROVIDING BASE BAND FOUR PLANE MONOPULSE, DYNAMICALLY ADJUSTABLE NULLS & POLARIZATION | Q1886497 | 0.019241 | Vacuum polarization | 7 |
0010ba9fc8850d94dbbaf1f967bfa36e99369fdb | A MMW POLARIZATION DIVERSE TRANSCEIVER SYSTEM PROVIDING BASE BAND FOUR PLANE MONOPULSE, DYNAMICALLY ADJUSTABLE NULLS & POLARIZATION | Q1050425 | 0.018615 | Polarization density | 8 |
0010ba9fc8850d94dbbaf1f967bfa36e99369fdb | A MMW POLARIZATION DIVERSE TRANSCEIVER SYSTEM PROVIDING BASE BAND FOUR PLANE MONOPULSE, DYNAMICALLY ADJUSTABLE NULLS & POLARIZATION | Q2698605 | 0.018496 | Polarization (electrochemistry) | 9 |
0010ba9fc8850d94dbbaf1f967bfa36e99369fdb | A MMW POLARIZATION DIVERSE TRANSCEIVER SYSTEM PROVIDING BASE BAND FOUR PLANE MONOPULSE, DYNAMICALLY ADJUSTABLE NULLS & POLARIZATION | Q962347 | 0.015278 | Spin polarization | 10 |
0010ba9fc8850d94dbbaf1f967bfa36e99369fdb | A MMW POLARIZATION DIVERSE TRANSCEIVER SYSTEM PROVIDING BASE BAND FOUR PLANE MONOPULSE, DYNAMICALLY ADJUSTABLE NULLS & POLARIZATION | Q7602059 | 0.013923 | Starlight | 11 |
0010ba9fc8850d94dbbaf1f967bfa36e99369fdb | A MMW POLARIZATION DIVERSE TRANSCEIVER SYSTEM PROVIDING BASE BAND FOUR PLANE MONOPULSE, DYNAMICALLY ADJUSTABLE NULLS & POLARIZATION | Q28452348 | 0.013535 | C band (NATO) | 12 |
0010ba9fc8850d94dbbaf1f967bfa36e99369fdb | A MMW POLARIZATION DIVERSE TRANSCEIVER SYSTEM PROVIDING BASE BAND FOUR PLANE MONOPULSE, DYNAMICALLY ADJUSTABLE NULLS & POLARIZATION | Q1641079 | 0.010915 | Hyperpolarization (physics) | 13 |
0010ba9fc8850d94dbbaf1f967bfa36e99369fdb | A MMW POLARIZATION DIVERSE TRANSCEIVER SYSTEM PROVIDING BASE BAND FOUR PLANE MONOPULSE, DYNAMICALLY ADJUSTABLE NULLS & POLARIZATION | Q496997 | 0.010777 | Indication (medicine) | 14 |
0010ba9fc8850d94dbbaf1f967bfa36e99369fdb | A MMW POLARIZATION DIVERSE TRANSCEIVER SYSTEM PROVIDING BASE BAND FOUR PLANE MONOPULSE, DYNAMICALLY ADJUSTABLE NULLS & POLARIZATION | Q7187858 | 0.010727 | Photon polarization | 15 |
0010ba9fc8850d94dbbaf1f967bfa36e99369fdb | A MMW POLARIZATION DIVERSE TRANSCEIVER SYSTEM PROVIDING BASE BAND FOUR PLANE MONOPULSE, DYNAMICALLY ADJUSTABLE NULLS & POLARIZATION | Q11942175 | 0.010316 | Polarizer | 16 |
0010ba9fc8850d94dbbaf1f967bfa36e99369fdb | A MMW POLARIZATION DIVERSE TRANSCEIVER SYSTEM PROVIDING BASE BAND FOUR PLANE MONOPULSE, DYNAMICALLY ADJUSTABLE NULLS & POLARIZATION | Q4854235 | 0.010188 | Band diagram | 17 |
0010ba9fc8850d94dbbaf1f967bfa36e99369fdb | A MMW POLARIZATION DIVERSE TRANSCEIVER SYSTEM PROVIDING BASE BAND FOUR PLANE MONOPULSE, DYNAMICALLY ADJUSTABLE NULLS & POLARIZATION | Q806380 | 0.009387 | Electronic band structure | 18 |
0010ba9fc8850d94dbbaf1f967bfa36e99369fdb | A MMW POLARIZATION DIVERSE TRANSCEIVER SYSTEM PROVIDING BASE BAND FOUR PLANE MONOPULSE, DYNAMICALLY ADJUSTABLE NULLS & POLARIZATION | Q204260 | 0.008398 | Plane (tool) | 19 |
0010ba9fc8850d94dbbaf1f967bfa36e99369fdb | A MMW POLARIZATION DIVERSE TRANSCEIVER SYSTEM PROVIDING BASE BAND FOUR PLANE MONOPULSE, DYNAMICALLY ADJUSTABLE NULLS & POLARIZATION | Q7554278 | 0.008133 | Reconfigurable antenna | 20 |
0010ba9fc8850d94dbbaf1f967bfa36e99369fdb | A MMW POLARIZATION DIVERSE TRANSCEIVER SYSTEM PROVIDING BASE BAND FOUR PLANE MONOPULSE, DYNAMICALLY ADJUSTABLE NULLS & POLARIZATION | Q2018880 | 0.007956 | S band | 21 |
0010ba9fc8850d94dbbaf1f967bfa36e99369fdb | A MMW POLARIZATION DIVERSE TRANSCEIVER SYSTEM PROVIDING BASE BAND FOUR PLANE MONOPULSE, DYNAMICALLY ADJUSTABLE NULLS & POLARIZATION | Q575724 | 0.007361 | Base | 22 |
0010ba9fc8850d94dbbaf1f967bfa36e99369fdb | A MMW POLARIZATION DIVERSE TRANSCEIVER SYSTEM PROVIDING BASE BAND FOUR PLANE MONOPULSE, DYNAMICALLY ADJUSTABLE NULLS & POLARIZATION | Q328998 | 0.007231 | Complex plane | 23 |
0010ba9fc8850d94dbbaf1f967bfa36e99369fdb | A MMW POLARIZATION DIVERSE TRANSCEIVER SYSTEM PROVIDING BASE BAND FOUR PLANE MONOPULSE, DYNAMICALLY ADJUSTABLE NULLS & POLARIZATION | Q17012331 | 0.007111 | Anatomical plane | 24 |
0010ba9fc8850d94dbbaf1f967bfa36e99369fdb | A MMW POLARIZATION DIVERSE TRANSCEIVER SYSTEM PROVIDING BASE BAND FOUR PLANE MONOPULSE, DYNAMICALLY ADJUSTABLE NULLS & POLARIZATION | Q4386425 | 0.007102 | Depolarizer | 25 |
0010ba9fc8850d94dbbaf1f967bfa36e99369fdb | A MMW POLARIZATION DIVERSE TRANSCEIVER SYSTEM PROVIDING BASE BAND FOUR PLANE MONOPULSE, DYNAMICALLY ADJUSTABLE NULLS & POLARIZATION | Q869891 | 0.006789 | Polarizability | 26 |
0010ba9fc8850d94dbbaf1f967bfa36e99369fdb | A MMW POLARIZATION DIVERSE TRANSCEIVER SYSTEM PROVIDING BASE BAND FOUR PLANE MONOPULSE, DYNAMICALLY ADJUSTABLE NULLS & POLARIZATION | Q21072584 | 0.005027 | Macrophage polarization | 27 |
0010ba9fc8850d94dbbaf1f967bfa36e99369fdb | A MMW POLARIZATION DIVERSE TRANSCEIVER SYSTEM PROVIDING BASE BAND FOUR PLANE MONOPULSE, DYNAMICALLY ADJUSTABLE NULLS & POLARIZATION | Q131214 | 0.004912 | Antenna (radio) | 28 |
0010ba9fc8850d94dbbaf1f967bfa36e99369fdb | A MMW POLARIZATION DIVERSE TRANSCEIVER SYSTEM PROVIDING BASE BAND FOUR PLANE MONOPULSE, DYNAMICALLY ADJUSTABLE NULLS & POLARIZATION | Q17152721 | 0.004552 | Shortwave bands | 29 |
0010ba9fc8850d94dbbaf1f967bfa36e99369fdb | A MMW POLARIZATION DIVERSE TRANSCEIVER SYSTEM PROVIDING BASE BAND FOUR PLANE MONOPULSE, DYNAMICALLY ADJUSTABLE NULLS & POLARIZATION | Q25110567 | 0.004426 | Frequency band | 30 |
00122948ee5cffbed489ed69ff0bb46cef3bf8f7 | In this proposal 21st Century Technologies will (1) conceptually combine multiple social network patterns to provide greater visibility and a deeper understanding of anomalous and possibly terrorist behaviors to support force protection (2) implementthese combined constructs into an social network pattern library usable for military security analysts and (3) integrate the library into TMODS. 21st Century Technologies', TMODS, (Terrorist Modus Operandi Detection System) ,currently being developed forDARPA under the EELD program, shall be used as a framework for the development of the library. The integrated social network pattern library shall be an add-on capability to TMODS. This approach provides intelligence analysts, who may not have socialnetwork or other types of expertise, the capability to identify threats based on a robust library of integrated social network pattern data. Technologies can be used to support force protection overseas as well as for homeland defense. | Q2715623 | 0.067548 | Social network | 1 |
00122948ee5cffbed489ed69ff0bb46cef3bf8f7 | In this proposal 21st Century Technologies will (1) conceptually combine multiple social network patterns to provide greater visibility and a deeper understanding of anomalous and possibly terrorist behaviors to support force protection (2) implementthese combined constructs into an social network pattern library usable for military security analysts and (3) integrate the library into TMODS. 21st Century Technologies', TMODS, (Terrorist Modus Operandi Detection System) ,currently being developed forDARPA under the EELD program, shall be used as a framework for the development of the library. The integrated social network pattern library shall be an add-on capability to TMODS. This approach provides intelligence analysts, who may not have socialnetwork or other types of expertise, the capability to identify threats based on a robust library of integrated social network pattern data. Technologies can be used to support force protection overseas as well as for homeland defense. | Q3277290 | 0.048792 | Force protection | 2 |
00122948ee5cffbed489ed69ff0bb46cef3bf8f7 | In this proposal 21st Century Technologies will (1) conceptually combine multiple social network patterns to provide greater visibility and a deeper understanding of anomalous and possibly terrorist behaviors to support force protection (2) implementthese combined constructs into an social network pattern library usable for military security analysts and (3) integrate the library into TMODS. 21st Century Technologies', TMODS, (Terrorist Modus Operandi Detection System) ,currently being developed forDARPA under the EELD program, shall be used as a framework for the development of the library. The integrated social network pattern library shall be an add-on capability to TMODS. This approach provides intelligence analysts, who may not have socialnetwork or other types of expertise, the capability to identify threats based on a robust library of integrated social network pattern data. Technologies can be used to support force protection overseas as well as for homeland defense. | Q11795082 | 0.035314 | Homeland defense | 3 |
00122948ee5cffbed489ed69ff0bb46cef3bf8f7 | In this proposal 21st Century Technologies will (1) conceptually combine multiple social network patterns to provide greater visibility and a deeper understanding of anomalous and possibly terrorist behaviors to support force protection (2) implementthese combined constructs into an social network pattern library usable for military security analysts and (3) integrate the library into TMODS. 21st Century Technologies', TMODS, (Terrorist Modus Operandi Detection System) ,currently being developed forDARPA under the EELD program, shall be used as a framework for the development of the library. The integrated social network pattern library shall be an add-on capability to TMODS. This approach provides intelligence analysts, who may not have socialnetwork or other types of expertise, the capability to identify threats based on a robust library of integrated social network pattern data. Technologies can be used to support force protection overseas as well as for homeland defense. | Q131454 | 0.028357 | Library of Congress | 4 |
00122948ee5cffbed489ed69ff0bb46cef3bf8f7 | In this proposal 21st Century Technologies will (1) conceptually combine multiple social network patterns to provide greater visibility and a deeper understanding of anomalous and possibly terrorist behaviors to support force protection (2) implementthese combined constructs into an social network pattern library usable for military security analysts and (3) integrate the library into TMODS. 21st Century Technologies', TMODS, (Terrorist Modus Operandi Detection System) ,currently being developed forDARPA under the EELD program, shall be used as a framework for the development of the library. The integrated social network pattern library shall be an add-on capability to TMODS. This approach provides intelligence analysts, who may not have socialnetwork or other types of expertise, the capability to identify threats based on a robust library of integrated social network pattern data. Technologies can be used to support force protection overseas as well as for homeland defense. | Q2273844 | 0.027662 | Social intelligence | 5 |
00122948ee5cffbed489ed69ff0bb46cef3bf8f7 | In this proposal 21st Century Technologies will (1) conceptually combine multiple social network patterns to provide greater visibility and a deeper understanding of anomalous and possibly terrorist behaviors to support force protection (2) implementthese combined constructs into an social network pattern library usable for military security analysts and (3) integrate the library into TMODS. 21st Century Technologies', TMODS, (Terrorist Modus Operandi Detection System) ,currently being developed forDARPA under the EELD program, shall be used as a framework for the development of the library. The integrated social network pattern library shall be an add-on capability to TMODS. This approach provides intelligence analysts, who may not have socialnetwork or other types of expertise, the capability to identify threats based on a robust library of integrated social network pattern data. Technologies can be used to support force protection overseas as well as for homeland defense. | Q5034471 | 0.024346 | Capability management | 6 |
00122948ee5cffbed489ed69ff0bb46cef3bf8f7 | In this proposal 21st Century Technologies will (1) conceptually combine multiple social network patterns to provide greater visibility and a deeper understanding of anomalous and possibly terrorist behaviors to support force protection (2) implementthese combined constructs into an social network pattern library usable for military security analysts and (3) integrate the library into TMODS. 21st Century Technologies', TMODS, (Terrorist Modus Operandi Detection System) ,currently being developed forDARPA under the EELD program, shall be used as a framework for the development of the library. The integrated social network pattern library shall be an add-on capability to TMODS. This approach provides intelligence analysts, who may not have socialnetwork or other types of expertise, the capability to identify threats based on a robust library of integrated social network pattern data. Technologies can be used to support force protection overseas as well as for homeland defense. | Q7075 | 0.024326 | Library | 7 |
00122948ee5cffbed489ed69ff0bb46cef3bf8f7 | In this proposal 21st Century Technologies will (1) conceptually combine multiple social network patterns to provide greater visibility and a deeper understanding of anomalous and possibly terrorist behaviors to support force protection (2) implementthese combined constructs into an social network pattern library usable for military security analysts and (3) integrate the library into TMODS. 21st Century Technologies', TMODS, (Terrorist Modus Operandi Detection System) ,currently being developed forDARPA under the EELD program, shall be used as a framework for the development of the library. The integrated social network pattern library shall be an add-on capability to TMODS. This approach provides intelligence analysts, who may not have socialnetwork or other types of expertise, the capability to identify threats based on a robust library of integrated social network pattern data. Technologies can be used to support force protection overseas as well as for homeland defense. | Q188860 | 0.02153 | Library (computing) | 8 |
00122948ee5cffbed489ed69ff0bb46cef3bf8f7 | In this proposal 21st Century Technologies will (1) conceptually combine multiple social network patterns to provide greater visibility and a deeper understanding of anomalous and possibly terrorist behaviors to support force protection (2) implementthese combined constructs into an social network pattern library usable for military security analysts and (3) integrate the library into TMODS. 21st Century Technologies', TMODS, (Terrorist Modus Operandi Detection System) ,currently being developed forDARPA under the EELD program, shall be used as a framework for the development of the library. The integrated social network pattern library shall be an add-on capability to TMODS. This approach provides intelligence analysts, who may not have socialnetwork or other types of expertise, the capability to identify threats based on a robust library of integrated social network pattern data. Technologies can be used to support force protection overseas as well as for homeland defense. | Q2297111 | 0.020008 | Social support | 9 |
00122948ee5cffbed489ed69ff0bb46cef3bf8f7 | In this proposal 21st Century Technologies will (1) conceptually combine multiple social network patterns to provide greater visibility and a deeper understanding of anomalous and possibly terrorist behaviors to support force protection (2) implementthese combined constructs into an social network pattern library usable for military security analysts and (3) integrate the library into TMODS. 21st Century Technologies', TMODS, (Terrorist Modus Operandi Detection System) ,currently being developed forDARPA under the EELD program, shall be used as a framework for the development of the library. The integrated social network pattern library shall be an add-on capability to TMODS. This approach provides intelligence analysts, who may not have socialnetwork or other types of expertise, the capability to identify threats based on a robust library of integrated social network pattern data. Technologies can be used to support force protection overseas as well as for homeland defense. | Q109406 | 0.019791 | Network | 10 |
End of preview.
README.md exists but content is empty.
- Downloads last month
- 42
Models trained or fine-tuned on mmitch25/sample_awards